US20080020026A1 - Hemostatic compositions and methods for controlling bleeding - Google Patents
Hemostatic compositions and methods for controlling bleeding Download PDFInfo
- Publication number
- US20080020026A1 US20080020026A1 US11/890,321 US89032107A US2008020026A1 US 20080020026 A1 US20080020026 A1 US 20080020026A1 US 89032107 A US89032107 A US 89032107A US 2008020026 A1 US2008020026 A1 US 2008020026A1
- Authority
- US
- United States
- Prior art keywords
- dextran
- linked
- polysaccharide
- cross
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- This invention relates to hemostatic compositions and methods employing the same, and more particularly to hemostatic compositions useful for controlling bleeding at active bleeding wound sites.
- Wounds are generally classified as acute or chronic in accordance with their healing tendencies.
- Acute wounds typically those received as a result of surgery or trauma, usually heal uneventfully within an expected time frame.
- Acute wounds include wounds such as active bleeding wound sites, e.g., wounds that have detectable, unclotted blood.
- active bleeding wound sites e.g., wounds that have detectable, unclotted blood.
- the rapid control of topical bleeding at active bleeding wound sites is of critical importance in wound management, especially for the management of trauma, e.g., as a result of military exercises or surgery.
- a conventional method of controlling bleeding at active bleeding wound sites advocates the use of cotton gauze pads capable of absorbing 250 ml of blood. Cotton pads are considered passive, however, because of their inability to initiate or accelerate blood clotting.
- Other formulations have been reported to promote hemostasis and are described in U.S. Pat. Nos. 6,454,787; 6,060,461; 5,196,190; 5,667,501; 4,793,336; 5,679,372; 5,098,417; and 4,405,324.
- a hemostatic composition capable of accelerating the coagulation cascade to form a thrombus would be useful.
- the invention relates to hemostatic compositions and methods for making and using the same in order to promote hemostasis at active bleeding wound sites.
- the present compositions typically include an article which contains cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose.
- a polysaccharide is ionically cross-linked and in association with an article comprising cellulose.
- Hemostatic compositions can include additional polysaccharides covalently linked to either or both of the cellulose and the first polysaccharide or physically trapped by a network formed by the covalent linking or ionic cross-linking of the first polysaccharide.
- a method for controlling bleeding at an active bleeding wound site of an animal includes applying a hemostatic composition to the active bleeding wound site.
- the hemostatic composition includes an article which contains cellulose and a polysaccharide, such as dextran, starch, or alginate, covalently linked to the cellulose. If dextran is used, it may be in the form of a bead, e.g., covalently cross-linked dextran beads.
- the molecular weight of the dextran can range from about 10,000 to about 2,000,000 Daltons, or from about 20,000 to about 100,000 Daltons. When a polysaccharide is linked to the cellulose, it can have a molecular weight exclusion limit of greater than about 30,000 Daltons.
- Articles which contain cellulose can be barriers, structures, or devices useful in surgery, diagnostic procedures, or wound treatment.
- an article containing cellulose can be a bandage, suture, dressing, gauze, gel, foam, web, film, tape, or patch.
- An article containing cellulose can include a cotton material, e.g., cotton gauze.
- the article can also optionally include adhesives or polymeric laminating materials.
- Hemostatic compositions of the present invention are useful for accelerating blood clotting at an active bleeding wound site.
- an active bleeding wound site Prior to the application of a hemostatic composition, an active bleeding wound site may be characterized in that it bleeds at a rate of from about 0.5 ml/min to about 1000 ml/min.
- the active bleeding wound site may bleed at a rate of less than 0.03 ml/min.
- the rate of less than 0.03 ml/min. may be achieved in from about 2 to about 20 minutes, and in certain embodiments in less than about 5 minutes.
- a hemostatic composition can comprise a second polysaccharide covalently linked to the cellulose and, optionally, to the first polysaccharide.
- the second polysaccharide may have a different molecular weight than the first polysaccharide.
- the second polysaccharide may be dextran having a molecular weight from about 800,000 to about 2M.
- the second polysaccharide may be physically trapped by the covalent linking of the first polysaccharide to the cellulose.
- hemostatic compositions of the present invention can include an article comprising cellulose in association with a polysaccharide ionically linked to itself (cross-linked).
- the article comprising cellulose may be coated with, immersed in, or soaked in the polysaccharide, which is subsequently ionically cross-linked.
- the polysaccharide may be further covalently linked to the cellulose of the article.
- the polysaccharide may be physically trapped in fibers of the article comprising cellulose.
- alginate can be ionically cross-linked to itself with metal cations, including Mg2+; Ni2+; Ca2+; Sr2+; Ba2+; Zn2+; Cd2+; Cu2+; Pb2+; Fe3+; and Al3+.
- the cation is Ca2+.
- a second polysaccharide, such as dextran can also be physically trapped, e.g., by the network formed by the ionic cross-linking of the first polysaccharide.
- Dextran can be in the form of cross-linked beads, e.g., dextran that has been previously cross-linked to itself. Dextran can be covalently linked to the bandage, e.g. by linking dextran to the cellulose with epichlorohydrin.
- a hemostatic composition can include dextran-alginate spheres, such as ionically linked dextran-alginate spheres, or covalently linked dextran-alginate spheres, or both ionically and covalently linked dextran-alginate spheres.
- hemostatic compositions include additional agents, such as analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, collagen, fibrinogen, fibrin, humectants, preservatives, lymphokines, cytokines, odor controlling materials, vitamins, and clotting factors.
- agents such as analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, collagen, fibrinogen, fibrin, hume
- Hemostatic compositions of the present invention can be made by incubating a linking agent with a polysaccharide and an article comprising cellulose to form a hemostatic composition having the polysaccharide covalently linked to the cellulose.
- the linking agent may be any linking agent useful for linking available hydroxyl groups on cellulose with available hydroxyl groups on a polysaccharide. Examples include epichlorohydrin, dichlorohydrin, diepoxyburan, disepoxypropyl ether, or ethylene-glyco-bis-epoxypropylether.
- the incubation step may occur in an aqueous alkaline solution. The temperature of the incubation step can range from about 40° C. to about 70° C. In certain embodiments, the temperature is about 50° C. The incubation step can occur for about 1 to about 24 hours. In addition, the incubation step can be in the presence of a stabilizing solution, e.g., a solution designed to prevent or limit evaporation of water.
- the stabilizing solution can include cellulose acetate butyrate.
- the covalently linked polysaccharide may have a molecular weight exclusion limit of greater than 30,000 Daltons.
- the polysaccharide is dextran.
- the dextran can be in the form of covalently cross-linked beads.
- the molecular weight of the dextran can range from about 10,000 to about 2M, or from about 20,000 to about 100,000 Daltons.
- the incubation step may be occur in an aqueous alkaline solution having about 12% to about 75% dextran.
- the invention provides a method of making a composition including incubating a polysaccharide and a cation with an article containing cellulose in order to form a hemostatic composition having the article containing cellulose in association with an ionically cross-linked polysaccharide.
- the polysaccharide may be further covalently linked to the cellulose.
- the cation may be, for example, Ca2+.
- the Ca2+ may be in the form of, or derived from, Ca2+-loaded cross-linked dextran beads.
- the polysaccharide may be sodium alginate or a derivative of alginic acid, including salts of alginic acid.
- the incubation step includes a second polysaccharide; the second polysaccharide may become physically trapped in the three dimensional network formed by the ionic cross-linking of the first polysaccharide.
- the second polysaccharide may be dextran, e.g., dextran in the form of cross-linked beads.
- the second polysaccharide may be further covalently linked to the cellulose, e.g., through a linking agent such as epichlorohydrin.
- the invention provides a method for manufacturing a composition, where the method includes the step of mixing an aqueous phase alkaline polysaccharide solution with an organic phase stabilizing agent solution to form a mixture having polysaccharide spheres; incubating a cross-linking agent with the mixture to cross-link the polysaccharide spheres; isolating the cross-linked polysaccharide spheres; and coating an article comprising a sodium alginate solution with the cross-linked polysaccharide spheres.
- the method can include removing the organic phase stabilizing agent from the mixture, e.g., prior to isolating the cross-linked polysaccharide spheres.
- the method can also include exposing the cross-linked polysaccharide spheres to a solution comprising Ca2+ ions, e.g., washing the cross-linked polysaccharide spheres in a Ca2+ solution.
- the polysaccharide may be dextran, and the organic phase stabilizing agent solution may include cellulose acetate butyrate.
- cross-linked polysaccharide spheres are between about 30 to about 500 ⁇ m in size.
- the mixing and incubating steps may occur at a temperature of from about 40° C. to about 70° C.
- the coating step can include spraying the article with the cross-linked polysaccharide spheres.
- the invention also relates to hemostatic compositions manufactured according to the above method.
- another method for manufacturing a composition includes the steps of providing an aqueous phase alkaline solution having dextran and sodium alginate therein; preparing dextran-alginate spheres from the aqueous phase alkaline solution; and incubating the dextran-alginate spheres with a linking agent to link said dextran-alginate spheres.
- Dextran-alginate spheres can be prepared by any method conventional in the art, including the use of a mechanical droplet generator.
- a linking agent may covalently or ionically link or cross-link the dextran-alginate spheres.
- a linking agent may be epichlorohydrin or a Ca2+-containing salt such as calcium chloride.
- the dextran-alginate spheres may be linked with a Ca2+ linking agent, and then linked with an epichlorohydrin linking agent, or the linking can be performed in the reverse order, or simultaneously.
- the method can further including coating, e.g., spraying, an article, such as an article comprising sodium alginate, with the linked dextran-alginate spheres.
- the invention also includes hemostatic compositions manufactured according to the method.
- linking or “linked” are meant to indicate either a covalent or ionic link, either direct or mediated by a chemical moiety or an ion, between two chemically distinct entities, e.g., dextran linked to cellulose.
- cross-link is meant to indicate a covalent or ionic link, either direct or mediated by a chemical moiety or ion, between two chemically similar moieties, e.g., dextran cross-linked to itself, alginate cross-linked to itself.
- the chemically similar moieties do not have to be identical.
- dextran having a particular average molecular weight range includes dextran molecules of a variety of molecular weights, and thus the dextran molecules are not identical but chemically similar.
- dextran molecules having an average molecular weight range are linked, e.g., covalently linked with epichlorohydrin, they are said to be “cross-linked.”
- spheres when used in the context of the present invention, are not meant to imply different sizes, but are meant to be interchangeable terms describing an embodiment of a composition.
- active bleeding wound site means, at a minimum, that unclotted blood is present in the wound, e.g., extravascular blood, particularly where the surface of a tissue has been broken or an artery, vein, or capillary system has been compromised.
- the rate of blood flow from an active bleeding wound site can vary, depending upon the nature of the wound. In some cases, an active bleeding wound site will exhibit blood flow at a rate from about at a rate of from about 0.5 ml/min to about 1000 ml/min. Some active bleeding wound sites may exhibit higher rates of blood flow, e.g., punctures of major arteries such as the aorta.
- the active bleeding wound site may bleed at a rate of less than 0.03 ml/min.
- the rate of less than 0.03 ml/min. may be achieved in from about 2 to about 20 minutes, and in certain embodiments in less than about 5 minutes.
- the invention relates to hemostatic compositions used to promote hemostasis at active bleeding wound sites. While not being bound by any theory, it is believed that the hemostatic compositions of the present invention control bleeding by initiating and accelerating blood clotting.
- the hemostatic compositions of the present invention activate platelets and concentrate high molecular weight components of the coagulation cascade (e.g., clotting factors) by excluding high molecular weight components of the cascade, while absorbing the lower molecular weight components in blood.
- coagulation cascade components having a molecular weight higher than about 30,000 Daltons are excluded, including fibrinogen (MW 340,000); prothrombin (MW 70,000); thrombin (MW 34,000); Factor V (MW 330,000); Factor VII (MW 50,000); Factor VIII (MW 320,000); von Willebrand factor (MW>850,000); Factor IX (MW 57,000); Factor X (MW 59,000); Factor XI (MW 143,000); Factor XII (MW 76,000); Factor XIII (MW 320,000); high MW kininogen (Fitzgerald Factor) (MW 120,000-200,000), and prekallikrein (Fletcher Factor) (MW 85,000-100,000).
- fibrinogen MW 340,000
- prothrombin MW 70,000
- thrombin MW 34,000
- Factor V MW 330,000
- Factor VII MW 50,000
- Factor VIII MW 320,000
- von Willebrand factor MW>850,000
- Factor IX
- Hemostatic compositions typically include an article comprising cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose.
- hemostatic compositions include an article comprising cellulose in association with a polysaccharide that is ionically cross-linked. The polysaccharide can be further covalently linked to the cellulose.
- Hemostatic compositions can include additional polysaccharides covalently linked to either or both of the cellulose and the first polysaccharide.
- Other embodiments of hemostatic compositions include linked and cross-linked polysaccharide spheres, optionally loaded with a cation, e.g., Ca2+.
- certain hemostatic compositions comprise both a macroscopic structure (e.g., an article) and a microscopic structure (e.g., networks of polysaccharide cross-linkages or networks of polysaccharide covalent linkages to cellulose).
- Some hemostatic compositions therefore form three dimensional networks of a polysaccharide, either as ionically linked chains or covalently bound to the cellulose of the article.
- a second polysaccharide may be physically trapped by the network formed by the first polysaccharide.
- a hemostatic composition includes an article containing cellulose and a polysaccharide, such as dextran, starch, or alginate, covalently linked to the cellulose.
- the article may include natural or synthetic celluloses (e.g., cellulose acetate, cellulose butyrate, cellulose propionate).
- the polysaccharide chosen should be safe for in vivo use, e.g., non-allergenic, non-toxic, and preferably non-metabolized. Polysaccharides for clinical use are known in the art and available from a variety of sources. See, e.g., U.S. Pat. No. 6,303,585.
- covalent linkages encompass bonds from any of the available chemical moieties of the polysaccharide to any of the available chemical moieties of the cellulose.
- hydroxyl moieties on dextran can be covalently linked to hydroxyl moieties on cellulose through the linking agent epichlorohydrin. In that case, a glyceryl bridge linking dextran to cellulose is formed.
- Flodin, P., and Ingelman, B. “Process for the Manufacture of Hydrophilic High Molecular Weight Substances,” British Patent No. 854,715; and Flodin, P. “Chapter 2: The Preparation of Dextran Gels,” Dextran Gels and Their Applications in Gel Filtration , Pharmacia, Uppsala Sweden, 1962, pages 14-26.
- the average molecular weight range of the polysaccharide can vary, but typically ranges from about 10,000 to about 2M Daltons.
- the molecular weight range chosen will affect the molecular weight exclusion limit of the covalently linked polysaccharide, and thus its ability to exclude the coagulation components and concentrate them.
- Dextran is a high molecular weight polysaccharide that is water-soluble. It is not metabolized by humans, and is non-toxic and tolerated well by most animals, including humans.
- the average molecular weight of dextran used in the present invention can range from about 10,000 to about 2,000,000 Daltons, or from about 20,000 to about 100,000 Daltons.
- Dextran can be in the form of beads, e.g., covalently cross-linked beads, before it is linked covalently to the cellulose.
- Dextran beads can exhibit a range of sizes, e.g., from about 30 to about 500 ⁇ m.
- Dextran beads are commercially available, e.g., as SephadexTM (Pharmacia); see, for example UK 974,054.
- dextran beads or particles may be formed during the preparation of the hemostatic composition, e.g., from the covalent cross-linking of previously uncross-linked dextran molecules.
- dextran may be in solution form, e.g., uncross-linked, before it is covalently linked to the cellulose.
- Dextran may be covalently linked to the cellulose and covalently cross-linked to itself, e.g., when exposed to a linking agent such as epichlorohydrin.
- the dextran molecules may coat all or a component of the article, such as fibers of a cotton bandage, so that it subsequently forms a three-dimensional microscopic linked network or mesh when it is covalently linked to the cellulose and covalently cross-linked to itself.
- Dextran beads linked to cellulose or a cellulose-dextran mesh as described previously contribute to the ability of a hemostatic composition to exclude high molecular weight components of the coagulation cascade.
- the average molecular weight of the polysaccharide, the degree of linking of the polysaccharide to cellulose, and any cross-linking of the polysaccharide (e.g., to itself) are factors in the molecular weight exclusion limit of the polysaccharide in a hemostatic composition and the water regain of a hemostatic composition.
- Water regain is defined as the weight of water taken up by 1 g of dry hemostatic composition and can be determined by methods known in the art. For example, it is known that small changes in dextran concentration or linking agent concentration (e.g., epichlorohydrin) can result in dramatic changes in water regain. Typically, at lower molecular weights of dextran, a higher water regain results. See Flodin, P., “Chapter 2: The Preparation of Dextran Gels,” Dextran Gels and Their Applications in Gel Filtration , Pharmacia, Uppsala Sweden, 1962, pages 14-26.
- the degree of hydration of the polysaccharide also affects the molecular weight exclusion limit. As the degree of hydration increases, the molecular weight exclusion limit of the polysaccharide usually increases. Typically, when dextran is linked to cellulose, the dextran will have a molecular weight exclusion limit of greater than about 30,000 Daltons, thus effectively excluding the components of the coagulation cascade and concentrating them on the microscopic surface of the hemostatic composition.
- Articles which contain cellulose can be any barriers, structures, or devices useful in surgery, diagnostic procedures, or wound treatment.
- an article containing cellulose can be a bandage, suture, dressing, gauze, gel, foam, web, film, tape, or patch.
- An article containing cellulose can include a cotton material, e.g., cotton gauze. The article should allow the polysaccharide linked to the cellulose to interact with the wound site.
- a hemostatic composition can comprise a second polysaccharide covalently linked to cellulose.
- the second polysaccharide may have a different molecular weight than the first polysaccharide.
- the second polysaccharide may be dextran having a molecular weight from about 800,000 to about 2M.
- the second polysaccharide may be covalently linked to the cellulose at a time after the first polysaccharide, at the same time as the first polysaccharide, or at a time before the first polysaccharide.
- hemostatic compositions of the present invention can include an article containing cellulose in association with an ionically cross-linked polysaccharide.
- the polysaccharide may be further covalently linked to the cellulose.
- ionic linkages include ion-mediated bonds between available chemical moieties on the polysaccharide.
- Typical chemical moieties that can be mediated with an ion include hydroxyl moieties.
- sodium alginate or alginic acid salts can be ionically linked with metal cations, including Mg2+, Ni2+, Ca2+, Sr2+, Ba2+, Zn2+, Cd2+, Cu2+, Pb2+, Fe3+, and Al3+.
- metal cations including Mg2+, Ni2+, Ca2+, Sr2+, Ba2+, Zn2+, Cd2+, Cu2+, Pb2+, Fe3+, and Al3+.
- Ca2+ may be used.
- the alginate can be of any type, including type G (L-guluronic acid) or type M (D-mannuronic acid), or mixed M and G.
- type G L-guluronic acid
- M D-mannuronic acid
- a second polysaccharide such as dextran
- Dextran can be in the form of covalently cross-linked beads, e.g., dextran that has been previously cross-linked to itself with epichlorohydrin, or SephadexTM beads.
- the dextran can be in solution form (e.g., uncross-linked), as described above.
- dextran can be covalently linked to the cellulose, e.g. by linking dextran to the cellulose with epichlorohydrin. Accordingly, dextran may become cross-linked to itself.
- hemostatic compositions include dextran-alginate spheres, such as ionically linked dextran-alginate spheres, or covalently linked dextran-alginate spheres, or both ionically and covalently linked dextran-alginate spheres.
- dextran-alginate spheres such as ionically linked dextran-alginate spheres, or covalently linked dextran-alginate spheres, or both ionically and covalently linked dextran-alginate spheres.
- cross-linked dextran spheres loaded with Ca2+ ions are also included as hemostatic compositions of the present invention.
- Hemostatic compositions can include additional agents, such as analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, collagen, fibrinogen, fibrin, humectants, preservatives, lymphokines, cytokines, odor controlling materials, vitamins, and clotting factors.
- additional agents such as analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, collagen, fibrinogen, fibrin,
- Hemostatic compositions may be used in combination with polymeric laminating materials and adhesives to provide both mechanical support and flexibility to an article and to facilitate adhesion to the wound. Additional information on such polymeric laminating materials and adhesives for use in the present invention can be found in, e.g., WO 00/27327.
- the present invention also contemplates pharmaceutical compositions comprising certain hemostatic compositions of the present invention, e.g., dextran-alginate linked spheres or calcium-loaded cross-linked dextran spheres.
- Pharmaceutical compositions may be formulated in conventional manners using one or more physiologically acceptable carriers containing excipients and auxiliaries. Proper formulation is dependent upon the route of administration chosen.
- a “pharmaceutically acceptable carrier” is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more hemostatic compositions to a subject.
- Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties, when combined with a hemostatic composition.
- Other components may be present in a pharmaceutical composition, if desired.
- compositions of the present invention can be administered by a number of methods depending upon the area to be treated. Administration can be, for example, topical or parenteral. Administration can be rapid (e.g., by injection) or can occur over a period of time. For treating tissues in the central nervous system, pharmaceutical compositions can be administered by injection or infusion into the cerebrospinal fluid, preferably with one or more agents capable of promoting penetration of the pharmaceutical composition across the blood-brain barrier.
- Formulations for topical administration include, for example, sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions in liquid or solid oil bases. Such solutions also can contain buffers, diluents and other suitable additives.
- Pharmaceutical compositions and formulations for topical administration can include patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- compositions and formulations for parenteral administration can include sterile aqueous solutions, which also can contain buffers, diluents and other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers).
- suitable additives e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers.
- compositions of the present invention include, but are not limited to, solutions, emulsions, aqueous suspensions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, for example, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.
- Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other; in general, emulsions are either of the water-in-oil (w/o) or oil-in-water (o/w) variety.
- Emulsion formulations have been widely used for oral delivery of therapeutics due to their ease of formulation and efficacy of solubilization, absorption, and bioavailability.
- compositions of the invention further encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.
- pharmaceutically acceptable salts refers to physiologically and pharmaceutically acceptable salts of the hemostatic compositions of the invention (i.e., salts that retain the desired biological activity without imparting undesired toxicological effects).
- salts formed with cations include, but are not limited to, salts formed with cations (e.g., sodium, potassium, calcium, or polyamines such as spermine); acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid); salts formed with organic acids (e.g., acetic acid, citric acid, oxalic acid, palmitic acid, or fumaric acid); and salts formed from elemental anions (e.g., chlorine, bromine, and iodine).
- cations e.g., sodium, potassium, calcium, or polyamines such as spermine
- inorganic acids e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid
- organic acids e.g., acetic acid, citric acid, oxalic acid, palmitic acid, or fumaric acid
- a method for controlling bleeding at an active bleeding wound site of an animal includes applying a hemostatic composition to the active bleeding wound site.
- Application of the hemostatic composition typically includes contacting the hemostatic composition with the wound or bleeding site surface.
- the hemostatic composition is maintained in contact with the wound or bleeding site for a period of time sufficient to control the bleeding, e.g., to clot the blood, slow the rate of bleeding, or stop the bleeding.
- the application may include the use of pressure, e.g., by using an elastic bandage to maintain contact with the bleeding site.
- an internal wound may be packed with a hemostatic composition until hemostasis is achieved.
- a hemostatic composition is delivered to the wound site.
- a catheter or needle may be used to deliver a hemostatic composition to an intravascular puncture site or to a biopsy site.
- the catheter or the needle may be optionally coated with a hemostatic composition of the present invention.
- a hemostatic composition can control bleeding, for example, to a rate of less than 0.03 ml/min, in a period of from about 2 to about 20 minutes. In certain embodiments, bleeding stops immediately, or in less than about 5 minutes.
- a hemostatic compositions of the present invention will be used to inhibit or completely stop bleeding of a parenchymal organ, such as the liver, kidney, spleen, pancreas, or lungs; or to control bleeding during surgery (e.g., abdominal, vascular, gynecological, dental, tissue transplantation surgery, etc.).
- percutaneous needle biopsies are common interventional medical procedures. Possible complications of needle biopsies, however, include bleeding at the biopsy site. The amount of bleeding is related to the needle size, tissue sample size, location of the biopsy, and vascularization of the tissue.
- Hemostatic compositions of the present invention can be used to promote hemostasis at needle biopsy sites. Biopsy needles may either be coated with hemostatic compositions of the present invention, or may be used to deliver a hemostatic composition to the biopsy site. For more information on biopsy tracts, see U.S. Pat. No. 6,447,534.
- catheterization and interventional procedures such as angioplasty and stenting, generally are performed by inserting a hollow needle through a patient's skin and muscle tissue into the vascular system.
- a guide wire is then typically passed through the needle lumen into a blood vessel.
- the needle is removed and an introducer sheath is advanced over the guide wire into the vessel, and a catheter is typically passed through the lumen of the introducer sheath and advanced over the guide wire for positioning.
- the catheter and introducer sheath are removed, often leaving a puncture site in the vessel, with associated bleeding.
- Hemostatic compositions of the present invention may be used to coat the exterior of catheters, stents, introducer sheath, and guide wires, etc., or may be delivered, e.g., via a catheter, to the puncture site in order to promote hemostasis.
- a catheter e.g., a catheter
- hemostatic compositions with varying water regains can be assembled (e.g., stacked in descending order) for use in major bleeding to attain hemostasis.
- the invention provides methods for making hemostatic compositions.
- the hemostatic compositions of the present invention can be made by incubating a linking agent with a polysaccharide and an article containing cellulose to form a hemostatic composition having the polysaccharide covalently linked to the cellulose.
- any biologically compatible bifunctional or heterobifunctional reagent may be used as the linking agent, including reagents with halogens, epoxides, hydroxy succinimide esters, aldehydes, activated thiols, or other moieties for reacting free amines, hydroxides, hydroxyls, or sulfhydryls on the bandage or on the polysaccharide.
- the bandage may be modified, e.g., derivatized, to incorporate reactive moieties such as amines or sulfhydryls for reacting with a particular linking agent.
- the polysaccharide may also be modified, e.g., derivatized, in a similar manner, provided that the polysaccharide so derivatized remains pharmaceutically suitable for animal, e.g., human use.
- the linking agent may be epichlorohydrin, dichlorohydrin, diepoxyburan, disepoxypropyl ether, or ethylene-glyco-bis-epoxypropylether.
- the incubation step may occur in an aqueous alkaline solution.
- the polysaccharide is from about 10% to about 80% wt/vol of the aqueous alkaline solution.
- the concentration of the linking agent in the incubation step can range from about 2% to about 20% wt/wt of the polysaccharide.
- the temperature of the incubation step can range from about 40° C. to about 70° C. In certain embodiments, the temperature is about 50° C.
- the incubation step can occur for about 1 to about 24 hours.
- the incubating step may also include agitation of the reagents.
- the incubation step can be in the presence of a stabilizing solution, e.g., a solution designed to prevent or limit evaporation of water.
- the stabilizing solution can include cellulose acetate butyrate.
- the method can also include neutralizing the aqueous alkaline solution, e.g., with an acid such as HCl at a concentration of from 1 to 5M.
- the hemostatic composition can be washed with an aqueous solution, e.g., distilled water, or an aqueous alcoholic wash, e.g., 50/50 vol/vol EtOH/water.
- the hemostatic composition can be serially washed in increasing amounts of an alcoholic wash, such as 25%, 50%, 75%, and 100% EtOH.
- the alcohol wash solution can contain a humectant, e.g., glycerin, at a concentration of about 0.1 to about 2.0%.
- the hemostatic composition can be dried, e.g., at about 50° C. to about 80° C. For example, the hemostatic composition can be dried at 70° C. After drying, the covalently linked polysaccharide may have a molecular weight exclusion limit of greater than 30,000 Daltons.
- the polysaccharide is dextran.
- the dextran can be in the form of covalently cross-linked beads.
- the molecular weight of the dextran can range from about 10,000 to about 2M, or from about 20,000 to about 100,000 Daltons. Typically, dextran of MW 40,000 is used.
- the incubation step may be occur in an aqueous alkaline solution having about 12 to about 75% dextran wt/vol.
- the invention provides a method of making a hemostatic composition including incubating a polysaccharide and a cation with an article containing cellulose in order to form a hemostatic composition having the article containing cellulose in association with an ionically cross-linked polysaccharide.
- the polysaccharide may be further covalently linked to the cellulose.
- the cation may be as described previously, including, for example, Ca2+.
- the Ca2+ may be in the form of, or derived from, Ca2+-loaded cross-linked, dextran beads.
- the polysaccharide may be sodium alginate or derivatives of alginic acid, including salts of alginic acid. Aqueous and alcoholic washes of the hemostatic composition can be performed, as described previously.
- the incubation step includes a second polysaccharide.
- the second polysaccharide may be dextran, e.g., dextran in the form of covalently cross-linked beads.
- the second polysaccharide may be physically trapped, e.g., in the three-dimensional network formed by the ionic cross-linking of the first polysaccharide.
- the second polysaccharide may be further covalently linked to the bandage, e.g., through a linking agent such as epichlorohydrin.
- an article such as cellulose gauze is immersed in a solution of a first polysaccharide (e.g., about 1 to 5% sodium alginate) and a second polysaccharide (e.g., 20% dextran, avg. molecular weight 40,000).
- the first polysaccharide is ionically cross-linked with a cation solution, e.g., Ca2+ from a solution having about 0.5 to about 10% aqueous calcium chloride.
- the Ca2+ concentration can be reduced with serial washes, e.g., to reduce the Ca2+ concentration to about 0.5% Ca2+.
- the first or second polysaccharide, or both may then be covalently linked to the cellulose and/or cross-linked using an aqueous alkaline solution (e.g., 20% NaOH) of a linking agent, e.g., epichlorohydrin (e.g., at about 3-6% of the weight of the second polysaccharide).
- a linking agent e.g., epichlorohydrin (e.g., at about 3-6% of the weight of the second polysaccharide).
- the resulting hemostatic composition may be dried as described previously.
- cross-linked polysaccharide spheres can be mixed with a Ca2+-alcoholic wash solution (e.g., 1% calcium chloride in neat alcohol).
- the cross-linked polysaccharide spheres can be purchased, e.g., as SephadexTM, or can be prepared from an aqueous alkaline polysaccharide solution and a cross-linking agent (e.g., dextran cross-linked with epichlorohydrin), as discussed previously.
- the cross-linked polysaccharide spheres After washing in the Ca2+-alcohol solution, the cross-linked polysaccharide spheres have Ca2+ in their pores, e.g., are Ca2+-loaded spheres, and can be used to coat an article, e.g., sprayed onto a bandage, that has been previously soaked or immersed in a polysaccharide solution, e.g., sodium alginate, at a concentration of about 0.5-5% polysaccharide.
- Ca2+ from the cross-linked spheres exchanges with the sodium from the sodium alginate solution, resulting in ionically cross-linked calcium alginate, which physically traps cross-linked polysaccharide spheres in the three-dimensional network of ionic bonding.
- the hemostatic composition so formed may be dried as discussed previously.
- the invention provides a method for manufacturing a composition, where the method includes the step of mixing an aqueous phase alkaline polysaccharide solution with an organic phase stabilizing agent solution to form a mixture having polysaccharide spheres; incubating a cross-linking agent with the mixture to cross-link the polysaccharide spheres; isolating the cross-linked polysaccharide spheres; and coating an article comprising a sodium alginate solution with the cross-linked polysaccharide spheres.
- the method can include removing the organic phase stabilizing agent from the mixture, e.g., prior to isolating the cross-linked polysaccharide spheres.
- the method can also include exposing the cross-linked polysaccharide spheres to a solution comprising Ca2+ ions, e.g., washing the cross-linked polysaccharide spheres in a Ca2+ solution.
- the polysaccharide may be dextran, and the organic phase stabilizing agent solution may include cellulose acetate butyrate.
- the cross-linked polysaccharide spheres are between about 30 to about 500 ⁇ m in size.
- the mixing and incubating steps may occur at a temperature of from about 40° C. to about 70° C.
- the coating step can include spraying the article with the cross-linked polysaccharide spheres.
- the invention also relates to hemostatic compositions manufactured according to the above method.
- another method for manufacturing a composition includes the steps of providing an aqueous phase alkaline solution having dextran and sodium alginate therein; preparing dextran-alginate spheres from the aqueous phase alkaline solution; and incubating the dextran-alginate spheres with a linking agent to form linked dextran-alginate spheres.
- the dextran-alginate spheres can be prepared by any method conventional in the art, including the use of a mechanical droplet generator or an air knife.
- the linking agent may covalently or ionically link and/or cross-link the dextran-alginate spheres.
- the linking agent may be epichlorohydrin or a cation as described previously, e.g., a Ca2+-containing salt.
- the dextran-alginate spheres may be first linked with a cation linking agent, and then linked with an epichlorohydrin linking agent, or vice versa.
- the dextran-alginate spheres may be linked simultaneously with a cation linking agent and an epichlorohydrin linking agent.
- the method can further including coating, e.g., spraying, an article with the linked dextran-alginate spheres.
- the invention also is directed to hemostatic compositions manufactured according to the method.
- compositions were incubated with dextran (40,000 MW) in an alkaline epichlorohydrin solution (20% dextran in NaOH wt/vol; epichlorohydrin at about 3 to 6% wt/wt dextran).
- the solutions were allowed to react for about 1 to about 16 hours at a temperature range from about ambient room temperature to about 60° C.
- the resulting cross-linking reactions were subsequently neutralized using a 1 to 5 Molar HCl solution.
- the cross-linked and linked dextran-cotton hemostatic compositions were washed about 4 times with distilled water. The products were further washed twice with a 50% distilled water/alcohol solution, then with a 75% alcohol solution, and lastly with a 100% alcohol solution, to remove excess epichlorohydrin. A final alcohol wash solution contained about 0.1 to about 2% glycerin to keep the composition from becoming brittle. The hemostatic composition was dried at about 70° C. overnight.
- a stabilizing agent such as cellulose acetate butyrate was dissolved in ethylene dichloride at 3% wt/vol and heated to about 50° C. while stirring at about 200 RPM in a 1-2 liter cylindrical reaction vessel.
- Dextran MW 40,000 was dissolved in water at 15% wt/vol with 5N NaOH at 2% of the dextran weight.
- the dextran solution was gradually added to the stabilizing mixture with continued heating and stirring.
- a cross-linking agent such as epichlorohydrin was added to the vessel at 20% of the dextran weight.
- the reaction formed cross-linked gel spheres in 1-3 hours, but was allowed to proceed up to 16 hours before termination.
- Acetone was added and decanted twice to remove the stabilizer (cellulose acetate butyrate).
- the spheres were then treated with NaOH (equal parts of 2N NaOH and 95% ethyl alcohol) for about 15 mins., and neutralized with dilute acid (1N HCl) before filtration and washing with water.
- the swollen spheres were shrunk with alcohol treatment (25, 50, 75, 100% serial alcohol washes).
- Dry calcium chloride was mixed with a second 100% alcohol wash solution (1% calcium chloride in alcohol), which was used to wash the cross-linked dextran particles.
- the alcohol was evaporated off, trapping the calcium in the pores of the dextran particles.
- the final products were dry cross-linked dextran-calcium ion compositions.
- compositions were immersed (dipped) into a sodium alginate liquid solution (0.5-4%). After removal from the solution, the wet sodium alginate coated cotton materials were sprayed or dusted with the cross-linked dextran calcium compositions. Calcium exchanged with sodium, resulting in cross-linked calcium alginate. The cotton-dextran-alginate hemostatic compositions were then dried at 70° C. overnight.
- Cotton gauzes were immersed in solutions of 1 to 5% sodium alginate and 20% dextran (40,000 MW). The mixtures were cross-linked and linked with about 0.5% to about 10% aqueous calcium chloride solution. The compositions were washed to reduce Ca2+ concentration to about 0.5% Ca2+.
- Dextran-alginate cross-linking solutions were prepared using an aqueous alkaline epichlorohydrin solution, where the concentration of the epichlorohydrin was from about 3 to about 6% by weight of the dextran.
- the solutions included about 20% NaOH.
- the resulting hemostatic compositions were allowed to dry at ambient to about 60° C. overnight.
- Dextran (MW 40,000) was dissolved in 1N NaOH at a range of 18-69% wt/vol of dextran in the alkaline solution.
- Epichlorohydrin was added to a concentration of 20% of the dextran by weight at room temperature.
- Pharmaceutically acceptable cotton (cellulose) gauzes were added to the alkaline epichlorohydrin solutions. The solutions were allowed to react with agitation at 25° C. to 70° C. The mixtures were heated until a cross-linked dextran-cellulose gel formed on the gauze fibers, from 1-6 hours, up to 24 hours.
- the water regain for the hemostatic compositions ranged from 2.5 ml/g to 35 ml/g.
- Dextran (MW 40,000) was dissolved in 1N NaOH (34% dextran wt/vol of the alkaline solution). Epichlorohydrin was added to a concentration of 20% of the dextran by weight at room temperature.
- a pharmaceutically acceptable cellulose fiber based composition 16-ply 4 ⁇ 4 gauze, was dipped in the alkaline epichlorohydrin solution to thoroughly coat the fibers with the reaction solution, then placed in a flat bottomed dish.
- a stabilizing solution of cellulose acetate butyrate in ethylene dichloride (3% wt/vol), which is immiscible in water, was used to cover the gauze.
- the gauze was heated at 50° C., with gentle rocking after 1 hr., until a cross-linked and linked dextran-cellulose gel formed on the gauze fibers, typically in about 2 to 3 hours. Heating was continued until the desired endpoint, up to 24 hours. Acetone was added and decanted twice to remove the stabilizer.
- the gauze was neutralized with dilute HCl and washed as described previously in aqueous alcohol and alcohol solutions and dried at about 70° C. overnight. The water regain was 15 ml/g.
- Dextran (MW 40,000) was dissolved in 1N NaOH and reacted with gauze in the presence of epichlorohydrin, followed by neutralization, washing, and drying as described above.
- Cellulose-dextran compositions were made by varying the volume of dextran in the solvent from 12 to 75 wt/vol to produce hemostatic composition with water regains ranging from 5 ml/g to 35 ml/g.
- the compositions can be assembled for use in major bleeding by stacking them in descending order (e.g., 35 ml/g to 5 ml/g) to attain hemostasis.
- a non-ionic polymer substance was dissolved in a suitable solvent with an alkaline solution added as a cross-linking catalyst.
- a stabilizer was dissolved in a solvent that was immiscible with the polymer solvent and placed in a cylindrical vessel. The stabilizer solution formed the continuous phase and was heated with regular stirring. When the polymer solution was added to the stabilizer solution, a biphasic system formed in which the polymer droplets became the dispersed phase.
- a bifunctional cross-linking agent was added to the system which caused co-polymerization (cross-linking) of the polymer to form gel spheres.
- Water regain was determined in order to classify the molecular sieving capability of the cross-linked polymer.
- Water regain can be determined by methods well known in the art, and generally involves hydrating 1 gram of dry composition, and determining the amount of water absorbed by the 1 g of the dry composition. Generally, greater swelling capacity relates to larger pores (e.g., less cross-linking) and a higher molecular weight exclusion.
- a stabilizing agent such as cellulose acetate butyrate was dissolved in ethylene dichloride at 3% wt/vol and heated to about 50° C. while stirring at about 200 RPM in a 1-2 liter cylindrical reaction vessel.
- Dextran MW 40,000
- the dextran solution was gradually added to the stabilizing mixture with continued heating and stirring.
- a cross-linking agent such as epichlorohydrin was added to the vessel at 20% of the dextran weight.
- the reaction formed cross-linked gel spheres in 1-3 hours, but was allowed to proceed up to 16 hours before termination.
- Acetone was added and decanted twice to remove the stabilizer (cellulose acetate butyrate).
- the spheres were then treated with NaOH (equal parts of 2N NaOH and 95% ethyl alcohol) for about 15 mins., and neutralized with dilute acid (1N HCl) before filtration and washing with water.
- the swollen spheres were shrunk with alcohol treatment (25, 50, 75, 100% serial alcohol washes) as described previously.
- a final alcohol wash contained calcium chloride (0.04-1%).
- the alcohol was evaporated by drying at about 70° C., thus trapping the calcium in the pores and on the surface of the dextran spheres.
- the final product was a dry cross-linked dextran-calcium ion composition.
- the water regain was 20 ml/g.
- a pharmaceutically acceptable cotton (cellulose) gauze was immersed in or sprayed with a sodium alginate solution (0.5-4%).
- the wet sodium alginate coated gauzes were sprayed or dusted with dextran-calcium spheres, prepared as described previously. Calcium exchanged with sodium in the alginate, resulting in cross-linked calcium alginate. Ionic bonds formed between cellulose, alginate, and dextran, thereby chemically incorporating the spheres into the gauze to form the hemostatic compositions.
- dextran (MW 40,000) was dissolved in 50 ml 2N NaOH and mixed with a 50 ml solution of 2% sodium alginate (43% dextran and 1% alginate in 100 ml of 1N NaOH).
- 50-200 ⁇ m dextran-alginate droplets were linked and cross-linked in a solution of 1.7% calcium chloride.
- the spheres were further linked and cross-linked by adding 7.2 ml epichlorohydrin to 100 ml of the calcium chloride solution at 45° C. with agitation. The reaction continued for up to 16 hours until the desired amount of linking and cross-linking occurred.
- the spheres were neutralized with dilute HCl, washed in increasing concentrations of alcohol (25, 50, 75, 100%) and dried at about 70° C. overnight. The water regain was 10 ml/g.
- Cross-linked and linked dextran-alginate spheres prepared as described previously, were washed in a final calcium chloride alcohol wash (0.04-1% calcium chloride). The alcohol was evaporated to trap the calcium in the pores of the spheres. The spheres were then chemically incorporated into gauze containing sodium alginate, as described previously.
- compositions having Dextrans of Different Molecular Weights having Dextrans of Different Molecular Weights
- dextran 100 g of dextran (MW 2,000,000) dissolved in 2000 ml 0.5N NaOH was mixed with 30 g of dextran spheres, prepared as described previously. The cross-linked spheres and dextran solutions were mixed, and 100 g epichlorohydrin added.
- a pharmaceutically acceptable cellulose gauze was placed in a flat bottomed dish and the alkaline epichlorohydrin/dextran sphere/dextran solution was slowly poured over the gauze to thoroughly coat the fibers with the dextran spheres and dextran solution The coated gauze was heated at 50° C. with gentle rocking, until a gel formed on the gauze fibers, typically in 1-2 hours. The coated gauze was removed from the solution and placed in a flat bottom dish and heating was continued until the desired end-point, approximately 8-12 hours. The gauze was neutralized, washed, and dried, as described previously.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 11/357,770 filed Feb. 17, 2006, which is a divisional of U.S. patent application Ser. No. 10/334,864 filed Dec. 31, 2002, which claims priority from U.S. Provisional Patent Application No. 60/343,247, filed Dec. 31, 2001, and from U.S. Provisional Patent Application No. 60/354,917, filed Feb. 11, 2002, all of which are incorporated herein by reference in their entirety.
- This invention relates to hemostatic compositions and methods employing the same, and more particularly to hemostatic compositions useful for controlling bleeding at active bleeding wound sites.
- Wounds are generally classified as acute or chronic in accordance with their healing tendencies. Acute wounds, typically those received as a result of surgery or trauma, usually heal uneventfully within an expected time frame. Acute wounds include wounds such as active bleeding wound sites, e.g., wounds that have detectable, unclotted blood. The rapid control of topical bleeding at active bleeding wound sites is of critical importance in wound management, especially for the management of trauma, e.g., as a result of military exercises or surgery.
- A conventional method of controlling bleeding at active bleeding wound sites, such as an external hemorrhage or a surgical wound, advocates the use of cotton gauze pads capable of absorbing 250 ml of blood. Cotton pads are considered passive, however, because of their inability to initiate or accelerate blood clotting. Other formulations have been reported to promote hemostasis and are described in U.S. Pat. Nos. 6,454,787; 6,060,461; 5,196,190; 5,667,501; 4,793,336; 5,679,372; 5,098,417; and 4,405,324. A hemostatic composition capable of accelerating the coagulation cascade to form a thrombus would be useful.
- Accordingly, the invention relates to hemostatic compositions and methods for making and using the same in order to promote hemostasis at active bleeding wound sites. The present compositions typically include an article which contains cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose. In other embodiments, a polysaccharide is ionically cross-linked and in association with an article comprising cellulose. Hemostatic compositions can include additional polysaccharides covalently linked to either or both of the cellulose and the first polysaccharide or physically trapped by a network formed by the covalent linking or ionic cross-linking of the first polysaccharide.
- In one aspect of the invention, a method for controlling bleeding at an active bleeding wound site of an animal is provided. The animal can be a mammal. For example, the animal can be a human, horse, bird, dog, cat, sheep, cow, or monkey. The method includes applying a hemostatic composition to the active bleeding wound site. The hemostatic composition includes an article which contains cellulose and a polysaccharide, such as dextran, starch, or alginate, covalently linked to the cellulose. If dextran is used, it may be in the form of a bead, e.g., covalently cross-linked dextran beads. The molecular weight of the dextran can range from about 10,000 to about 2,000,000 Daltons, or from about 20,000 to about 100,000 Daltons. When a polysaccharide is linked to the cellulose, it can have a molecular weight exclusion limit of greater than about 30,000 Daltons.
- Articles which contain cellulose can be barriers, structures, or devices useful in surgery, diagnostic procedures, or wound treatment. For example, an article containing cellulose can be a bandage, suture, dressing, gauze, gel, foam, web, film, tape, or patch. An article containing cellulose can include a cotton material, e.g., cotton gauze. The article can also optionally include adhesives or polymeric laminating materials.
- Hemostatic compositions of the present invention are useful for accelerating blood clotting at an active bleeding wound site. Prior to the application of a hemostatic composition, an active bleeding wound site may be characterized in that it bleeds at a rate of from about 0.5 ml/min to about 1000 ml/min. After application of a hemostatic composition, the active bleeding wound site may bleed at a rate of less than 0.03 ml/min. For example, the rate of less than 0.03 ml/min. may be achieved in from about 2 to about 20 minutes, and in certain embodiments in less than about 5 minutes.
- A hemostatic composition can comprise a second polysaccharide covalently linked to the cellulose and, optionally, to the first polysaccharide. The second polysaccharide may have a different molecular weight than the first polysaccharide. For example, the second polysaccharide may be dextran having a molecular weight from about 800,000 to about 2M. Alternatively, the second polysaccharide may be physically trapped by the covalent linking of the first polysaccharide to the cellulose.
- In other embodiments, hemostatic compositions of the present invention can include an article comprising cellulose in association with a polysaccharide ionically linked to itself (cross-linked). For example, the article comprising cellulose may be coated with, immersed in, or soaked in the polysaccharide, which is subsequently ionically cross-linked. The polysaccharide may be further covalently linked to the cellulose of the article. In addition, in certain embodiments, the polysaccharide may be physically trapped in fibers of the article comprising cellulose.
- One example of a polysaccharide that can be ionically cross-linked is alginate. Alginate can be ionically cross-linked to itself with metal cations, including Mg2+; Ni2+; Ca2+; Sr2+; Ba2+; Zn2+; Cd2+; Cu2+; Pb2+; Fe3+; and Al3+. In some embodiments, the cation is Ca2+. A second polysaccharide, such as dextran, can also be physically trapped, e.g., by the network formed by the ionic cross-linking of the first polysaccharide. Dextran can be in the form of cross-linked beads, e.g., dextran that has been previously cross-linked to itself. Dextran can be covalently linked to the bandage, e.g. by linking dextran to the cellulose with epichlorohydrin.
- In another aspect, a hemostatic composition can include dextran-alginate spheres, such as ionically linked dextran-alginate spheres, or covalently linked dextran-alginate spheres, or both ionically and covalently linked dextran-alginate spheres.
- In another aspect of the invention, hemostatic compositions are provided that include additional agents, such as analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, collagen, fibrinogen, fibrin, humectants, preservatives, lymphokines, cytokines, odor controlling materials, vitamins, and clotting factors.
- The invention also provides methods for making hemostatic compositions. Hemostatic compositions of the present invention can be made by incubating a linking agent with a polysaccharide and an article comprising cellulose to form a hemostatic composition having the polysaccharide covalently linked to the cellulose.
- The linking agent may be any linking agent useful for linking available hydroxyl groups on cellulose with available hydroxyl groups on a polysaccharide. Examples include epichlorohydrin, dichlorohydrin, diepoxyburan, disepoxypropyl ether, or ethylene-glyco-bis-epoxypropylether. The incubation step may occur in an aqueous alkaline solution. The temperature of the incubation step can range from about 40° C. to about 70° C. In certain embodiments, the temperature is about 50° C. The incubation step can occur for about 1 to about 24 hours. In addition, the incubation step can be in the presence of a stabilizing solution, e.g., a solution designed to prevent or limit evaporation of water. The stabilizing solution can include cellulose acetate butyrate. The covalently linked polysaccharide may have a molecular weight exclusion limit of greater than 30,000 Daltons.
- In certain embodiments of the method, the polysaccharide is dextran. The dextran can be in the form of covalently cross-linked beads. The molecular weight of the dextran can range from about 10,000 to about 2M, or from about 20,000 to about 100,000 Daltons. The incubation step may be occur in an aqueous alkaline solution having about 12% to about 75% dextran.
- In another aspect, the invention provides a method of making a composition including incubating a polysaccharide and a cation with an article containing cellulose in order to form a hemostatic composition having the article containing cellulose in association with an ionically cross-linked polysaccharide. The polysaccharide may be further covalently linked to the cellulose. The cation may be, for example, Ca2+. The Ca2+ may be in the form of, or derived from, Ca2+-loaded cross-linked dextran beads. The polysaccharide may be sodium alginate or a derivative of alginic acid, including salts of alginic acid.
- In certain embodiments, the incubation step includes a second polysaccharide; the second polysaccharide may become physically trapped in the three dimensional network formed by the ionic cross-linking of the first polysaccharide. The second polysaccharide may be dextran, e.g., dextran in the form of cross-linked beads. The second polysaccharide may be further covalently linked to the cellulose, e.g., through a linking agent such as epichlorohydrin.
- In another aspect, the invention provides a method for manufacturing a composition, where the method includes the step of mixing an aqueous phase alkaline polysaccharide solution with an organic phase stabilizing agent solution to form a mixture having polysaccharide spheres; incubating a cross-linking agent with the mixture to cross-link the polysaccharide spheres; isolating the cross-linked polysaccharide spheres; and coating an article comprising a sodium alginate solution with the cross-linked polysaccharide spheres. The method can include removing the organic phase stabilizing agent from the mixture, e.g., prior to isolating the cross-linked polysaccharide spheres. The method can also include exposing the cross-linked polysaccharide spheres to a solution comprising Ca2+ ions, e.g., washing the cross-linked polysaccharide spheres in a Ca2+ solution. The polysaccharide may be dextran, and the organic phase stabilizing agent solution may include cellulose acetate butyrate.
- In certain embodiments of the method, cross-linked polysaccharide spheres are between about 30 to about 500 μm in size. The mixing and incubating steps may occur at a temperature of from about 40° C. to about 70° C. The coating step can include spraying the article with the cross-linked polysaccharide spheres. The invention also relates to hemostatic compositions manufactured according to the above method.
- In a further aspect, another method for manufacturing a composition is provided. The method includes the steps of providing an aqueous phase alkaline solution having dextran and sodium alginate therein; preparing dextran-alginate spheres from the aqueous phase alkaline solution; and incubating the dextran-alginate spheres with a linking agent to link said dextran-alginate spheres. Dextran-alginate spheres can be prepared by any method conventional in the art, including the use of a mechanical droplet generator. A linking agent may covalently or ionically link or cross-link the dextran-alginate spheres. Accordingly, a linking agent may be epichlorohydrin or a Ca2+-containing salt such as calcium chloride. The dextran-alginate spheres may be linked with a Ca2+ linking agent, and then linked with an epichlorohydrin linking agent, or the linking can be performed in the reverse order, or simultaneously. The method can further including coating, e.g., spraying, an article, such as an article comprising sodium alginate, with the linked dextran-alginate spheres. The invention also includes hemostatic compositions manufactured according to the method.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patents, patent applications, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not meant to be limiting.
- The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
- Like reference symbols in the various drawings indicate like elements.
- As used herein, the terms “linking” or “linked” are meant to indicate either a covalent or ionic link, either direct or mediated by a chemical moiety or an ion, between two chemically distinct entities, e.g., dextran linked to cellulose. The term “cross-link” is meant to indicate a covalent or ionic link, either direct or mediated by a chemical moiety or ion, between two chemically similar moieties, e.g., dextran cross-linked to itself, alginate cross-linked to itself. The chemically similar moieties do not have to be identical. For example, dextran having a particular average molecular weight range includes dextran molecules of a variety of molecular weights, and thus the dextran molecules are not identical but chemically similar. When dextran molecules having an average molecular weight range are linked, e.g., covalently linked with epichlorohydrin, they are said to be “cross-linked.”
- The terms “spheres,” “particles,” or “beads,” when used in the context of the present invention, are not meant to imply different sizes, but are meant to be interchangeable terms describing an embodiment of a composition.
- The term “active bleeding wound site” means, at a minimum, that unclotted blood is present in the wound, e.g., extravascular blood, particularly where the surface of a tissue has been broken or an artery, vein, or capillary system has been compromised. The rate of blood flow from an active bleeding wound site can vary, depending upon the nature of the wound. In some cases, an active bleeding wound site will exhibit blood flow at a rate from about at a rate of from about 0.5 ml/min to about 1000 ml/min. Some active bleeding wound sites may exhibit higher rates of blood flow, e.g., punctures of major arteries such as the aorta. After application of the hemostatic composition, the active bleeding wound site may bleed at a rate of less than 0.03 ml/min. For example, the rate of less than 0.03 ml/min. may be achieved in from about 2 to about 20 minutes, and in certain embodiments in less than about 5 minutes.
- Hemostatic Compositions
- The invention relates to hemostatic compositions used to promote hemostasis at active bleeding wound sites. While not being bound by any theory, it is believed that the hemostatic compositions of the present invention control bleeding by initiating and accelerating blood clotting. The hemostatic compositions of the present invention activate platelets and concentrate high molecular weight components of the coagulation cascade (e.g., clotting factors) by excluding high molecular weight components of the cascade, while absorbing the lower molecular weight components in blood. Accordingly, coagulation cascade components having a molecular weight higher than about 30,000 Daltons are excluded, including fibrinogen (MW 340,000); prothrombin (MW 70,000); thrombin (MW 34,000); Factor V (MW 330,000); Factor VII (MW 50,000); Factor VIII (MW 320,000); von Willebrand factor (MW>850,000); Factor IX (MW 57,000); Factor X (MW 59,000); Factor XI (MW 143,000); Factor XII (MW 76,000); Factor XIII (MW 320,000); high MW kininogen (Fitzgerald Factor) (MW 120,000-200,000), and prekallikrein (Fletcher Factor) (MW 85,000-100,000). In addition, laboratory experiments indicate that platelets aggregate around the hemostatic compositions of the present invention when exposed to blood. The net result is that concentrated clotting factors (coagulation cascade components) and activated platelets activate the conversion of prothrombin to thrombin in the presence of Ca2+, which subsequently catalyzes the conversion of fibrinogen to insoluble fibrin multimers, e.g., a fibrin clot. Additional information on the clotting cascade and hemostatic compositions containing fibrin can be found in U.S. Pat. No. 5,773,033.
- Hemostatic compositions typically include an article comprising cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose. In other embodiments, hemostatic compositions include an article comprising cellulose in association with a polysaccharide that is ionically cross-linked. The polysaccharide can be further covalently linked to the cellulose. Hemostatic compositions can include additional polysaccharides covalently linked to either or both of the cellulose and the first polysaccharide. Other embodiments of hemostatic compositions include linked and cross-linked polysaccharide spheres, optionally loaded with a cation, e.g., Ca2+.
- It should be noted that certain hemostatic compositions comprise both a macroscopic structure (e.g., an article) and a microscopic structure (e.g., networks of polysaccharide cross-linkages or networks of polysaccharide covalent linkages to cellulose). Some hemostatic compositions therefore form three dimensional networks of a polysaccharide, either as ionically linked chains or covalently bound to the cellulose of the article. Accordingly, in some embodiments, a second polysaccharide may be physically trapped by the network formed by the first polysaccharide.
- Accordingly, in one aspect, a hemostatic composition includes an article containing cellulose and a polysaccharide, such as dextran, starch, or alginate, covalently linked to the cellulose. The article may include natural or synthetic celluloses (e.g., cellulose acetate, cellulose butyrate, cellulose propionate). The polysaccharide chosen should be safe for in vivo use, e.g., non-allergenic, non-toxic, and preferably non-metabolized. Polysaccharides for clinical use are known in the art and available from a variety of sources. See, e.g., U.S. Pat. No. 6,303,585.
- As used herein, covalent linkages encompass bonds from any of the available chemical moieties of the polysaccharide to any of the available chemical moieties of the cellulose. For example, if the polysaccharide dextran is used, hydroxyl moieties on dextran can be covalently linked to hydroxyl moieties on cellulose through the linking agent epichlorohydrin. In that case, a glyceryl bridge linking dextran to cellulose is formed. For additional information, see Flodin, P., and Ingelman, B., “Process for the Manufacture of Hydrophilic High Molecular Weight Substances,” British Patent No. 854,715; and Flodin, P. “Chapter 2: The Preparation of Dextran Gels,” Dextran Gels and Their Applications in Gel Filtration, Pharmacia, Uppsala Sweden, 1962, pages 14-26.
- The average molecular weight range of the polysaccharide can vary, but typically ranges from about 10,000 to about 2M Daltons. The molecular weight range chosen will affect the molecular weight exclusion limit of the covalently linked polysaccharide, and thus its ability to exclude the coagulation components and concentrate them.
- Dextran is a high molecular weight polysaccharide that is water-soluble. It is not metabolized by humans, and is non-toxic and tolerated well by most animals, including humans. The average molecular weight of dextran used in the present invention can range from about 10,000 to about 2,000,000 Daltons, or from about 20,000 to about 100,000 Daltons.
- Dextran can be in the form of beads, e.g., covalently cross-linked beads, before it is linked covalently to the cellulose. Dextran beads can exhibit a range of sizes, e.g., from about 30 to about 500 μm. Dextran beads are commercially available, e.g., as Sephadex™ (Pharmacia); see, for example UK 974,054. Alternatively, dextran beads or particles may be formed during the preparation of the hemostatic composition, e.g., from the covalent cross-linking of previously uncross-linked dextran molecules.
- In other embodiments, dextran may be in solution form, e.g., uncross-linked, before it is covalently linked to the cellulose. Dextran may be covalently linked to the cellulose and covalently cross-linked to itself, e.g., when exposed to a linking agent such as epichlorohydrin. When dextran is in solution form (e.g., uncross-linked), the dextran molecules may coat all or a component of the article, such as fibers of a cotton bandage, so that it subsequently forms a three-dimensional microscopic linked network or mesh when it is covalently linked to the cellulose and covalently cross-linked to itself. Dextran beads linked to cellulose or a cellulose-dextran mesh as described previously contribute to the ability of a hemostatic composition to exclude high molecular weight components of the coagulation cascade.
- The average molecular weight of the polysaccharide, the degree of linking of the polysaccharide to cellulose, and any cross-linking of the polysaccharide (e.g., to itself) are factors in the molecular weight exclusion limit of the polysaccharide in a hemostatic composition and the water regain of a hemostatic composition. Water regain is defined as the weight of water taken up by 1 g of dry hemostatic composition and can be determined by methods known in the art. For example, it is known that small changes in dextran concentration or linking agent concentration (e.g., epichlorohydrin) can result in dramatic changes in water regain. Typically, at lower molecular weights of dextran, a higher water regain results. See Flodin, P., “Chapter 2: The Preparation of Dextran Gels,” Dextran Gels and Their Applications in Gel Filtration, Pharmacia, Uppsala Sweden, 1962, pages 14-26.
- Similarly, the degree of hydration of the polysaccharide also affects the molecular weight exclusion limit. As the degree of hydration increases, the molecular weight exclusion limit of the polysaccharide usually increases. Typically, when dextran is linked to cellulose, the dextran will have a molecular weight exclusion limit of greater than about 30,000 Daltons, thus effectively excluding the components of the coagulation cascade and concentrating them on the microscopic surface of the hemostatic composition.
- Articles which contain cellulose can be any barriers, structures, or devices useful in surgery, diagnostic procedures, or wound treatment. For example, an article containing cellulose can be a bandage, suture, dressing, gauze, gel, foam, web, film, tape, or patch. An article containing cellulose can include a cotton material, e.g., cotton gauze. The article should allow the polysaccharide linked to the cellulose to interact with the wound site.
- A hemostatic composition can comprise a second polysaccharide covalently linked to cellulose. The second polysaccharide may have a different molecular weight than the first polysaccharide. For example, the second polysaccharide may be dextran having a molecular weight from about 800,000 to about 2M. The second polysaccharide may be covalently linked to the cellulose at a time after the first polysaccharide, at the same time as the first polysaccharide, or at a time before the first polysaccharide.
- In other embodiments, hemostatic compositions of the present invention can include an article containing cellulose in association with an ionically cross-linked polysaccharide. The polysaccharide may be further covalently linked to the cellulose. In this context, ionic linkages include ion-mediated bonds between available chemical moieties on the polysaccharide. Typical chemical moieties that can be mediated with an ion (e.g., a cation) include hydroxyl moieties. For example, sodium alginate or alginic acid salts can be ionically linked with metal cations, including Mg2+, Ni2+, Ca2+, Sr2+, Ba2+, Zn2+, Cd2+, Cu2+, Pb2+, Fe3+, and Al3+. Typically, Ca2+ may be used. The alginate can be of any type, including type G (L-guluronic acid) or type M (D-mannuronic acid), or mixed M and G. For more information on alginate, see U.S. Pat. No. 5,144,016.
- In certain embodiments, a second polysaccharide, such as dextran, can be physically trapped in the network formed by the ionic cross-linking of the first polysaccharide. Dextran can be in the form of covalently cross-linked beads, e.g., dextran that has been previously cross-linked to itself with epichlorohydrin, or Sephadex™ beads. Alternatively, the dextran can be in solution form (e.g., uncross-linked), as described above. In addition, dextran can be covalently linked to the cellulose, e.g. by linking dextran to the cellulose with epichlorohydrin. Accordingly, dextran may become cross-linked to itself.
- Other embodiments of hemostatic compositions include dextran-alginate spheres, such as ionically linked dextran-alginate spheres, or covalently linked dextran-alginate spheres, or both ionically and covalently linked dextran-alginate spheres. In addition, cross-linked dextran spheres loaded with Ca2+ ions are also included as hemostatic compositions of the present invention.
- Hemostatic compositions can include additional agents, such as analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, collagen, fibrinogen, fibrin, humectants, preservatives, lymphokines, cytokines, odor controlling materials, vitamins, and clotting factors. For further information on these additional agents for incorporation, refer to WO 00/27327.
- Hemostatic compositions may be used in combination with polymeric laminating materials and adhesives to provide both mechanical support and flexibility to an article and to facilitate adhesion to the wound. Additional information on such polymeric laminating materials and adhesives for use in the present invention can be found in, e.g., WO 00/27327.
- Pharmaceutical Compositions
- The present invention also contemplates pharmaceutical compositions comprising certain hemostatic compositions of the present invention, e.g., dextran-alginate linked spheres or calcium-loaded cross-linked dextran spheres. Pharmaceutical compositions may be formulated in conventional manners using one or more physiologically acceptable carriers containing excipients and auxiliaries. Proper formulation is dependent upon the route of administration chosen.
- A “pharmaceutically acceptable carrier” (also referred to herein as an “excipient”) is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more hemostatic compositions to a subject. Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties, when combined with a hemostatic composition. Other components may be present in a pharmaceutical composition, if desired.
- Pharmaceutical compositions of the present invention can be administered by a number of methods depending upon the area to be treated. Administration can be, for example, topical or parenteral. Administration can be rapid (e.g., by injection) or can occur over a period of time. For treating tissues in the central nervous system, pharmaceutical compositions can be administered by injection or infusion into the cerebrospinal fluid, preferably with one or more agents capable of promoting penetration of the pharmaceutical composition across the blood-brain barrier.
- Formulations for topical administration include, for example, sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions in liquid or solid oil bases. Such solutions also can contain buffers, diluents and other suitable additives. Pharmaceutical compositions and formulations for topical administration can include patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- Compositions and formulations for parenteral administration can include sterile aqueous solutions, which also can contain buffers, diluents and other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers).
- Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, aqueous suspensions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, for example, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other; in general, emulsions are either of the water-in-oil (w/o) or oil-in-water (o/w) variety. Emulsion formulations have been widely used for oral delivery of therapeutics due to their ease of formulation and efficacy of solubilization, absorption, and bioavailability.
- Pharmaceutical compositions of the invention further encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the hemostatic compositions of the invention (i.e., salts that retain the desired biological activity without imparting undesired toxicological effects). Examples of pharmaceutically acceptable salts include, but are not limited to, salts formed with cations (e.g., sodium, potassium, calcium, or polyamines such as spermine); acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid); salts formed with organic acids (e.g., acetic acid, citric acid, oxalic acid, palmitic acid, or fumaric acid); and salts formed from elemental anions (e.g., chlorine, bromine, and iodine).
- Methods of Controlling Bleeding
- In one aspect of the invention, a method for controlling bleeding at an active bleeding wound site of an animal is provided. The method includes applying a hemostatic composition to the active bleeding wound site. Application of the hemostatic composition typically includes contacting the hemostatic composition with the wound or bleeding site surface. The hemostatic composition is maintained in contact with the wound or bleeding site for a period of time sufficient to control the bleeding, e.g., to clot the blood, slow the rate of bleeding, or stop the bleeding. The application may include the use of pressure, e.g., by using an elastic bandage to maintain contact with the bleeding site. Alternatively, an internal wound may be packed with a hemostatic composition until hemostasis is achieved. In other embodiments, a hemostatic composition is delivered to the wound site. For example, a catheter or needle may be used to deliver a hemostatic composition to an intravascular puncture site or to a biopsy site. The catheter or the needle may be optionally coated with a hemostatic composition of the present invention.
- Usually a hemostatic composition can control bleeding, for example, to a rate of less than 0.03 ml/min, in a period of from about 2 to about 20 minutes. In certain embodiments, bleeding stops immediately, or in less than about 5 minutes.
- Typically a hemostatic compositions of the present invention will be used to inhibit or completely stop bleeding of a parenchymal organ, such as the liver, kidney, spleen, pancreas, or lungs; or to control bleeding during surgery (e.g., abdominal, vascular, gynecological, dental, tissue transplantation surgery, etc.). For example, percutaneous needle biopsies are common interventional medical procedures. Possible complications of needle biopsies, however, include bleeding at the biopsy site. The amount of bleeding is related to the needle size, tissue sample size, location of the biopsy, and vascularization of the tissue. Hemostatic compositions of the present invention can be used to promote hemostasis at needle biopsy sites. Biopsy needles may either be coated with hemostatic compositions of the present invention, or may be used to deliver a hemostatic composition to the biopsy site. For more information on biopsy tracts, see U.S. Pat. No. 6,447,534.
- Similarly, catheterization and interventional procedures, such as angioplasty and stenting, generally are performed by inserting a hollow needle through a patient's skin and muscle tissue into the vascular system. A guide wire is then typically passed through the needle lumen into a blood vessel. The needle is removed and an introducer sheath is advanced over the guide wire into the vessel, and a catheter is typically passed through the lumen of the introducer sheath and advanced over the guide wire for positioning. Upon completion of the medical procedure, the catheter and introducer sheath are removed, often leaving a puncture site in the vessel, with associated bleeding. Hemostatic compositions of the present invention may be used to coat the exterior of catheters, stents, introducer sheath, and guide wires, etc., or may be delivered, e.g., via a catheter, to the puncture site in order to promote hemostasis. For additional information, see U.S. Pat. No. 6,391,048.
- The amount of hemostatic composition to be used will vary with the patient, the wound, and the composition employed. For example, hemostatic compositions with varying water regains can be assembled (e.g., stacked in descending order) for use in major bleeding to attain hemostasis.
- Methods for Making Hemostatic Compositions
- In another aspect, the invention provides methods for making hemostatic compositions. The hemostatic compositions of the present invention can be made by incubating a linking agent with a polysaccharide and an article containing cellulose to form a hemostatic composition having the polysaccharide covalently linked to the cellulose.
- Any biologically compatible bifunctional or heterobifunctional reagent may be used as the linking agent, including reagents with halogens, epoxides, hydroxy succinimide esters, aldehydes, activated thiols, or other moieties for reacting free amines, hydroxides, hydroxyls, or sulfhydryls on the bandage or on the polysaccharide. The bandage may be modified, e.g., derivatized, to incorporate reactive moieties such as amines or sulfhydryls for reacting with a particular linking agent. The polysaccharide may also be modified, e.g., derivatized, in a similar manner, provided that the polysaccharide so derivatized remains pharmaceutically suitable for animal, e.g., human use. The linking agent may be epichlorohydrin, dichlorohydrin, diepoxyburan, disepoxypropyl ether, or ethylene-glyco-bis-epoxypropylether. For additional information, see Flodin, P., and Ingelman, B., “Process for the Manufacture of Hydrophilic High Molecular Weight Substances,” British Patent No. 854,715; and Flodin, P., “Chapter 2: The Preparation of Dextran Gels,” Dextran Gels and Their Applications in Gel Filtration, Pharmacia, Uppsala Sweden, 1962, pages 14-26.
- The incubation step may occur in an aqueous alkaline solution. Typically, the polysaccharide is from about 10% to about 80% wt/vol of the aqueous alkaline solution. The concentration of the linking agent in the incubation step can range from about 2% to about 20% wt/wt of the polysaccharide.
- The temperature of the incubation step can range from about 40° C. to about 70° C. In certain embodiments, the temperature is about 50° C. The incubation step can occur for about 1 to about 24 hours. The incubating step may also include agitation of the reagents. In addition, the incubation step can be in the presence of a stabilizing solution, e.g., a solution designed to prevent or limit evaporation of water. The stabilizing solution can include cellulose acetate butyrate. The method can also include neutralizing the aqueous alkaline solution, e.g., with an acid such as HCl at a concentration of from 1 to 5M.
- The hemostatic composition can be washed with an aqueous solution, e.g., distilled water, or an aqueous alcoholic wash, e.g., 50/50 vol/vol EtOH/water. The hemostatic composition can be serially washed in increasing amounts of an alcoholic wash, such as 25%, 50%, 75%, and 100% EtOH. The alcohol wash solution can contain a humectant, e.g., glycerin, at a concentration of about 0.1 to about 2.0%. The hemostatic composition can be dried, e.g., at about 50° C. to about 80° C. For example, the hemostatic composition can be dried at 70° C. After drying, the covalently linked polysaccharide may have a molecular weight exclusion limit of greater than 30,000 Daltons.
- In certain embodiments of the method, the polysaccharide is dextran. The dextran can be in the form of covalently cross-linked beads. The molecular weight of the dextran can range from about 10,000 to about 2M, or from about 20,000 to about 100,000 Daltons. Typically, dextran of MW 40,000 is used. The incubation step may be occur in an aqueous alkaline solution having about 12 to about 75% dextran wt/vol.
- In another aspect, the invention provides a method of making a hemostatic composition including incubating a polysaccharide and a cation with an article containing cellulose in order to form a hemostatic composition having the article containing cellulose in association with an ionically cross-linked polysaccharide. The polysaccharide may be further covalently linked to the cellulose. The cation may be as described previously, including, for example, Ca2+. The Ca2+ may be in the form of, or derived from, Ca2+-loaded cross-linked, dextran beads. The polysaccharide may be sodium alginate or derivatives of alginic acid, including salts of alginic acid. Aqueous and alcoholic washes of the hemostatic composition can be performed, as described previously.
- In certain embodiments, the incubation step includes a second polysaccharide. The second polysaccharide may be dextran, e.g., dextran in the form of covalently cross-linked beads. The second polysaccharide may be physically trapped, e.g., in the three-dimensional network formed by the ionic cross-linking of the first polysaccharide. The second polysaccharide may be further covalently linked to the bandage, e.g., through a linking agent such as epichlorohydrin.
- In one embodiment, an article such as cellulose gauze is immersed in a solution of a first polysaccharide (e.g., about 1 to 5% sodium alginate) and a second polysaccharide (e.g., 20% dextran, avg. molecular weight 40,000). The first polysaccharide is ionically cross-linked with a cation solution, e.g., Ca2+ from a solution having about 0.5 to about 10% aqueous calcium chloride. The Ca2+ concentration can be reduced with serial washes, e.g., to reduce the Ca2+ concentration to about 0.5% Ca2+. The first or second polysaccharide, or both, may then be covalently linked to the cellulose and/or cross-linked using an aqueous alkaline solution (e.g., 20% NaOH) of a linking agent, e.g., epichlorohydrin (e.g., at about 3-6% of the weight of the second polysaccharide). The resulting hemostatic composition may be dried as described previously.
- In another embodiment of the present invention, cross-linked polysaccharide spheres can be mixed with a Ca2+-alcoholic wash solution (e.g., 1% calcium chloride in neat alcohol). The cross-linked polysaccharide spheres can be purchased, e.g., as Sephadex™, or can be prepared from an aqueous alkaline polysaccharide solution and a cross-linking agent (e.g., dextran cross-linked with epichlorohydrin), as discussed previously. After washing in the Ca2+-alcohol solution, the cross-linked polysaccharide spheres have Ca2+ in their pores, e.g., are Ca2+-loaded spheres, and can be used to coat an article, e.g., sprayed onto a bandage, that has been previously soaked or immersed in a polysaccharide solution, e.g., sodium alginate, at a concentration of about 0.5-5% polysaccharide. In certain embodiments, Ca2+ from the cross-linked spheres exchanges with the sodium from the sodium alginate solution, resulting in ionically cross-linked calcium alginate, which physically traps cross-linked polysaccharide spheres in the three-dimensional network of ionic bonding. The hemostatic composition so formed may be dried as discussed previously.
- In another aspect, the invention provides a method for manufacturing a composition, where the method includes the step of mixing an aqueous phase alkaline polysaccharide solution with an organic phase stabilizing agent solution to form a mixture having polysaccharide spheres; incubating a cross-linking agent with the mixture to cross-link the polysaccharide spheres; isolating the cross-linked polysaccharide spheres; and coating an article comprising a sodium alginate solution with the cross-linked polysaccharide spheres. The method can include removing the organic phase stabilizing agent from the mixture, e.g., prior to isolating the cross-linked polysaccharide spheres. The method can also include exposing the cross-linked polysaccharide spheres to a solution comprising Ca2+ ions, e.g., washing the cross-linked polysaccharide spheres in a Ca2+ solution. The polysaccharide may be dextran, and the organic phase stabilizing agent solution may include cellulose acetate butyrate.
- In certain embodiments of the method, the cross-linked polysaccharide spheres are between about 30 to about 500 μm in size. The mixing and incubating steps may occur at a temperature of from about 40° C. to about 70° C. The coating step can include spraying the article with the cross-linked polysaccharide spheres. The invention also relates to hemostatic compositions manufactured according to the above method.
- In a further aspect, another method for manufacturing a composition is provided. The method includes the steps of providing an aqueous phase alkaline solution having dextran and sodium alginate therein; preparing dextran-alginate spheres from the aqueous phase alkaline solution; and incubating the dextran-alginate spheres with a linking agent to form linked dextran-alginate spheres. The dextran-alginate spheres can be prepared by any method conventional in the art, including the use of a mechanical droplet generator or an air knife.
- The linking agent may covalently or ionically link and/or cross-link the dextran-alginate spheres. Accordingly, the linking agent may be epichlorohydrin or a cation as described previously, e.g., a Ca2+-containing salt. The dextran-alginate spheres may be first linked with a cation linking agent, and then linked with an epichlorohydrin linking agent, or vice versa. The dextran-alginate spheres may be linked simultaneously with a cation linking agent and an epichlorohydrin linking agent. The method can further including coating, e.g., spraying, an article with the linked dextran-alginate spheres. The invention also is directed to hemostatic compositions manufactured according to the method.
- A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
- Pharmaceutically acceptable cotton-based compositions were incubated with dextran (40,000 MW) in an alkaline epichlorohydrin solution (20% dextran in NaOH wt/vol; epichlorohydrin at about 3 to 6% wt/wt dextran). The solutions were allowed to react for about 1 to about 16 hours at a temperature range from about ambient room temperature to about 60° C. The resulting cross-linking reactions were subsequently neutralized using a 1 to 5 Molar HCl solution.
- The cross-linked and linked dextran-cotton hemostatic compositions were washed about 4 times with distilled water. The products were further washed twice with a 50% distilled water/alcohol solution, then with a 75% alcohol solution, and lastly with a 100% alcohol solution, to remove excess epichlorohydrin. A final alcohol wash solution contained about 0.1 to about 2% glycerin to keep the composition from becoming brittle. The hemostatic composition was dried at about 70° C. overnight.
- A stabilizing agent, such as cellulose acetate butyrate was dissolved in ethylene dichloride at 3% wt/vol and heated to about 50° C. while stirring at about 200 RPM in a 1-2 liter cylindrical reaction vessel. Dextran (MW 40,000) was dissolved in water at 15% wt/vol with 5N NaOH at 2% of the dextran weight. The dextran solution was gradually added to the stabilizing mixture with continued heating and stirring. When droplets of the desired size were formed (30-500 μm), a cross-linking agent such as epichlorohydrin was added to the vessel at 20% of the dextran weight. The reaction formed cross-linked gel spheres in 1-3 hours, but was allowed to proceed up to 16 hours before termination. Acetone was added and decanted twice to remove the stabilizer (cellulose acetate butyrate). The spheres were then treated with NaOH (equal parts of 2N NaOH and 95% ethyl alcohol) for about 15 mins., and neutralized with dilute acid (1N HCl) before filtration and washing with water. The swollen spheres were shrunk with alcohol treatment (25, 50, 75, 100% serial alcohol washes).
- Dry calcium chloride was mixed with a second 100% alcohol wash solution (1% calcium chloride in alcohol), which was used to wash the cross-linked dextran particles. The alcohol was evaporated off, trapping the calcium in the pores of the dextran particles. The final products were dry cross-linked dextran-calcium ion compositions.
- Pharmaceutically acceptable cotton-based compositions were immersed (dipped) into a sodium alginate liquid solution (0.5-4%). After removal from the solution, the wet sodium alginate coated cotton materials were sprayed or dusted with the cross-linked dextran calcium compositions. Calcium exchanged with sodium, resulting in cross-linked calcium alginate. The cotton-dextran-alginate hemostatic compositions were then dried at 70° C. overnight.
- Cotton gauzes were immersed in solutions of 1 to 5% sodium alginate and 20% dextran (40,000 MW). The mixtures were cross-linked and linked with about 0.5% to about 10% aqueous calcium chloride solution. The compositions were washed to reduce Ca2+ concentration to about 0.5% Ca2+.
- Dextran-alginate cross-linking solutions were prepared using an aqueous alkaline epichlorohydrin solution, where the concentration of the epichlorohydrin was from about 3 to about 6% by weight of the dextran. The solutions included about 20% NaOH. The resulting hemostatic compositions were allowed to dry at ambient to about 60° C. overnight.
- Dextran (MW 40,000) was dissolved in 1N NaOH at a range of 18-69% wt/vol of dextran in the alkaline solution. Epichlorohydrin was added to a concentration of 20% of the dextran by weight at room temperature. Pharmaceutically acceptable cotton (cellulose) gauzes were added to the alkaline epichlorohydrin solutions. The solutions were allowed to react with agitation at 25° C. to 70° C. The mixtures were heated until a cross-linked dextran-cellulose gel formed on the gauze fibers, from 1-6 hours, up to 24 hours. After neutralization with dilute HCl (1N), successive washes removed excess reaction products and impurities: four times in distilled water, then with increasing concentrations of alcohol (25, 50, 75, 100%). A final alcohol wash of 100% EtOH contained from 0.1 to 2.0% glycerin to keep the compositions pliable. The resulting hemostatic compositions were dried at about 70° C. overnight.
- The water regain for the hemostatic compositions ranged from 2.5 ml/g to 35 ml/g. For information on water regain, see Flodin, P., Dextran Gels and Their Applications in Gel Filtration, Pharmacia, Uppsala Sweden, 1962, pages 31-32.
- 150 g of dextran (MW 40,000) was dissolved in 300 ml 1N NaOH. 30 g epichlorohydrin was quickly mixed with the dextran solution at room temperature. A pharmaceutically acceptable cellulose gauze was dipped in the alkaline epichlorohydrin solution to thoroughly coat the fibers with the reaction solution, then placed in a flat-bottomed dish. The gauze was heated to 50° C. in a humidified atmosphere, with gentle rocking after 1 hour, until a dextran-cellulose gel formed on the gauze fibers, typically in 1-2 hours. Heating was continued until the desired end-point, up to 24 hours. The gauze was neutralized, washed, treated with glycerin, and dried as described previously. The water regain was 7.5 ml/g.
- Dextran (MW 40,000) was dissolved in 1N NaOH (34% dextran wt/vol of the alkaline solution). Epichlorohydrin was added to a concentration of 20% of the dextran by weight at room temperature. A pharmaceutically acceptable cellulose fiber based composition, 16-ply 4×4 gauze, was dipped in the alkaline epichlorohydrin solution to thoroughly coat the fibers with the reaction solution, then placed in a flat bottomed dish. To prevent concentrating the reaction solution by evaporation, a stabilizing solution of cellulose acetate butyrate in ethylene dichloride (3% wt/vol), which is immiscible in water, was used to cover the gauze. The gauze was heated at 50° C., with gentle rocking after 1 hr., until a cross-linked and linked dextran-cellulose gel formed on the gauze fibers, typically in about 2 to 3 hours. Heating was continued until the desired endpoint, up to 24 hours. Acetone was added and decanted twice to remove the stabilizer. The gauze was neutralized with dilute HCl and washed as described previously in aqueous alcohol and alcohol solutions and dried at about 70° C. overnight. The water regain was 15 ml/g.
- Dextran (MW 40,000) was dissolved in 1N NaOH and reacted with gauze in the presence of epichlorohydrin, followed by neutralization, washing, and drying as described above. Cellulose-dextran compositions were made by varying the volume of dextran in the solvent from 12 to 75 wt/vol to produce hemostatic composition with water regains ranging from 5 ml/g to 35 ml/g. The compositions can be assembled for use in major bleeding by stacking them in descending order (e.g., 35 ml/g to 5 ml/g) to attain hemostasis.
- A non-ionic polymer substance was dissolved in a suitable solvent with an alkaline solution added as a cross-linking catalyst. A stabilizer was dissolved in a solvent that was immiscible with the polymer solvent and placed in a cylindrical vessel. The stabilizer solution formed the continuous phase and was heated with regular stirring. When the polymer solution was added to the stabilizer solution, a biphasic system formed in which the polymer droplets became the dispersed phase. A bifunctional cross-linking agent was added to the system which caused co-polymerization (cross-linking) of the polymer to form gel spheres.
- After purification and drying, the water regain of the spheres was determined in order to classify the molecular sieving capability of the cross-linked polymer. Water regain can be determined by methods well known in the art, and generally involves hydrating 1 gram of dry composition, and determining the amount of water absorbed by the 1 g of the dry composition. Generally, greater swelling capacity relates to larger pores (e.g., less cross-linking) and a higher molecular weight exclusion.
- More specifically, a stabilizing agent, such as cellulose acetate butyrate was dissolved in ethylene dichloride at 3% wt/vol and heated to about 50° C. while stirring at about 200 RPM in a 1-2 liter cylindrical reaction vessel. Dextran (MW 40,000) was dissolved in water at 15% wt/vol with 5N NaOH at 2% of the dextran weight. The dextran solution was gradually added to the stabilizing mixture with continued heating and stirring. When droplets of the desired size were formed (30-500 μm), a cross-linking agent such as epichlorohydrin was added to the vessel at 20% of the dextran weight. The reaction formed cross-linked gel spheres in 1-3 hours, but was allowed to proceed up to 16 hours before termination. Acetone was added and decanted twice to remove the stabilizer (cellulose acetate butyrate). The spheres were then treated with NaOH (equal parts of 2N NaOH and 95% ethyl alcohol) for about 15 mins., and neutralized with dilute acid (1N HCl) before filtration and washing with water. The swollen spheres were shrunk with alcohol treatment (25, 50, 75, 100% serial alcohol washes) as described previously. A final alcohol wash contained calcium chloride (0.04-1%). The alcohol was evaporated by drying at about 70° C., thus trapping the calcium in the pores and on the surface of the dextran spheres. The final product was a dry cross-linked dextran-calcium ion composition. The water regain was 20 ml/g.
- A pharmaceutically acceptable cotton (cellulose) gauze was immersed in or sprayed with a sodium alginate solution (0.5-4%). The wet sodium alginate coated gauzes were sprayed or dusted with dextran-calcium spheres, prepared as described previously. Calcium exchanged with sodium in the alginate, resulting in cross-linked calcium alginate. Ionic bonds formed between cellulose, alginate, and dextran, thereby chemically incorporating the spheres into the gauze to form the hemostatic compositions.
- 43 g dextran (MW 40,000) was dissolved in 50 ml 2N NaOH and mixed with a 50 ml solution of 2% sodium alginate (43% dextran and 1% alginate in 100 ml of 1N NaOH). 50-200 μm dextran-alginate droplets were linked and cross-linked in a solution of 1.7% calcium chloride. The spheres were further linked and cross-linked by adding 7.2 ml epichlorohydrin to 100 ml of the calcium chloride solution at 45° C. with agitation. The reaction continued for up to 16 hours until the desired amount of linking and cross-linking occurred. The spheres were neutralized with dilute HCl, washed in increasing concentrations of alcohol (25, 50, 75, 100%) and dried at about 70° C. overnight. The water regain was 10 ml/g.
- Cross-linked and linked dextran-alginate spheres, prepared as described previously, were washed in a final calcium chloride alcohol wash (0.04-1% calcium chloride). The alcohol was evaporated to trap the calcium in the pores of the spheres. The spheres were then chemically incorporated into gauze containing sodium alginate, as described previously.
- 100 g of dextran (MW 2,000,000) dissolved in 2000 ml 0.5N NaOH was mixed with 30 g of dextran spheres, prepared as described previously. The cross-linked spheres and dextran solutions were mixed, and 100 g epichlorohydrin added. A pharmaceutically acceptable cellulose gauze was placed in a flat bottomed dish and the alkaline epichlorohydrin/dextran sphere/dextran solution was slowly poured over the gauze to thoroughly coat the fibers with the dextran spheres and dextran solution The coated gauze was heated at 50° C. with gentle rocking, until a gel formed on the gauze fibers, typically in 1-2 hours. The coated gauze was removed from the solution and placed in a flat bottom dish and heating was continued until the desired end-point, approximately 8-12 hours. The gauze was neutralized, washed, and dried, as described previously.
- Two different alginates (G, M) were applied in 0.5% and/or 1% concentrations to 12-ply 2×2 cotton gauze squares, Type VII, in either 2 or 4 mL amounts. 0.5 g of calcium-dextran spheres (containing 3, 6, 12, or 24 mM calcium) were ionically bonded to the sodium alginate on the gauze. Freshly drawn human blood was added to each test sample, with 0.5 mls added to each calcium-dextran-alginate gauze and 0.1 ml added to the calcium-dextran spheres alone. Gauze immersed only in sodium alginate was used as a control.
- The blood added to the calcium-dextran spheres clotted upon contact. All of the calcium-dextran-alginate gauzes clotted the blood in less than 5 minutes, whereas alginate only gauzes produced weakly clotted blood in>5 mins. See Table 1 below.
TABLE 1 Clotting Times for Hemostatic Compositions gauze + 4 gauze + 4 gauze + 2 gauze + 4 ml .5% ml 1% ml 1% ml 1% alginate G alginate G alginate G alginate M 0 mM Ca++ >5 min. >5 min. >5 min. >5 min. control 3 mM Ca++ instantly not tested <5 min. not tested not tested dextran spheres 6 mM Ca++ instantly <5 min. <5 min. <5 min. <5 min. dextran spheres 12 mM instantly <5 min. <5 min. <5 min. <5 min. Ca++ dextran spheres 24 mM instantly <5 min. <5 min. <5 min. <5 min. Ca++ dextran spheres
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/890,321 US20080020026A1 (en) | 2001-12-31 | 2007-08-06 | Hemostatic compositions and methods for controlling bleeding |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34324701P | 2001-12-31 | 2001-12-31 | |
US35491702P | 2002-02-11 | 2002-02-11 | |
US10/334,864 US7101862B2 (en) | 2001-12-31 | 2002-12-31 | Hemostatic compositions and methods for controlling bleeding |
US11/357,770 US20060141018A1 (en) | 2001-12-31 | 2006-02-17 | Hemostatic compositions and methods for controlling bleeding |
US11/890,321 US20080020026A1 (en) | 2001-12-31 | 2007-08-06 | Hemostatic compositions and methods for controlling bleeding |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/357,770 Continuation US20060141018A1 (en) | 2001-12-31 | 2006-02-17 | Hemostatic compositions and methods for controlling bleeding |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080020026A1 true US20080020026A1 (en) | 2008-01-24 |
Family
ID=26993389
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/334,864 Expired - Fee Related US7101862B2 (en) | 2001-12-31 | 2002-12-31 | Hemostatic compositions and methods for controlling bleeding |
US11/357,770 Abandoned US20060141018A1 (en) | 2001-12-31 | 2006-02-17 | Hemostatic compositions and methods for controlling bleeding |
US11/890,321 Abandoned US20080020026A1 (en) | 2001-12-31 | 2007-08-06 | Hemostatic compositions and methods for controlling bleeding |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/334,864 Expired - Fee Related US7101862B2 (en) | 2001-12-31 | 2002-12-31 | Hemostatic compositions and methods for controlling bleeding |
US11/357,770 Abandoned US20060141018A1 (en) | 2001-12-31 | 2006-02-17 | Hemostatic compositions and methods for controlling bleeding |
Country Status (7)
Country | Link |
---|---|
US (3) | US7101862B2 (en) |
EP (1) | EP1469865A4 (en) |
JP (1) | JP2005514105A (en) |
AU (1) | AU2002361902A1 (en) |
CA (1) | CA2471994A1 (en) |
MX (1) | MXPA04006438A (en) |
WO (1) | WO2003057072A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090275904A1 (en) * | 2008-05-02 | 2009-11-05 | Sardesai Neil Rajendra | Sheet assemblies with releasable medicaments |
WO2010140146A2 (en) | 2009-06-01 | 2010-12-09 | Technion - Research & Development Foundation Ltd | Sealants, manufacturing thereof, and applications thereof |
WO2014145714A1 (en) * | 2013-01-17 | 2014-09-18 | Tattoo Innovations, Inc. | Hydrogel tattoo protection and aftercare system |
US20140370074A1 (en) * | 2007-11-05 | 2014-12-18 | Technion Research & Development Foundation Ltd. | Adhering composition and methods of applying the same |
US20190054203A1 (en) * | 2015-11-08 | 2019-02-21 | Omrix Biopharmaceuticals Ltd. | Hemostatic mixture of cellulose-based short and long fibers |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69941498D1 (en) * | 1998-11-12 | 2009-11-12 | Internat Mfg Group Inc | Hemostatic cross-linked dextran beads useful for rapid blood clotting and hemostasis |
US20070009586A1 (en) * | 2000-02-29 | 2007-01-11 | Cohen Kelman I | Wound dressings containing complexes of transition metals and alginate for elastase sequestering |
US6891077B2 (en) * | 2001-07-25 | 2005-05-10 | The United States Of America As Represented By The Secretary Of The Army | Fibrinogen bandages and arterial bleeding models and methods of making and using thereof |
US7670623B2 (en) | 2002-05-31 | 2010-03-02 | Materials Modification, Inc. | Hemostatic composition |
WO2005027808A1 (en) | 2003-09-12 | 2005-03-31 | Z-Medica Corporation | Calcium zeolite hemostatic agent |
ATE489062T1 (en) * | 2003-09-12 | 2010-12-15 | Z Medica Corp | PARTIALLY HYDROGENATED HEMOSTATIC AGENT |
US20050136773A1 (en) * | 2003-12-22 | 2005-06-23 | Kimberly-Clark Worldwide, Inc. | Treated nonwoven material |
US7737214B2 (en) * | 2004-03-15 | 2010-06-15 | Terumo Kabushiki Kaisha | Adhesion preventive material |
SE0403070D0 (en) * | 2004-12-16 | 2004-12-16 | Radi Medical Systems | Closure Device |
US20060178609A1 (en) * | 2005-02-09 | 2006-08-10 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
JP2008531498A (en) | 2005-02-15 | 2008-08-14 | バージニア コモンウェルス ユニバーシティ | Mineral technology (MT) for emergency hemostasis and treatment of acute wounds and chronic ulcers |
US9326995B2 (en) | 2005-04-04 | 2016-05-03 | The Regents Of The University Of California | Oxides for wound healing and body repair |
US20060282046A1 (en) * | 2005-04-13 | 2006-12-14 | Horn Jeffrey L | Device and method for subcutaneous delivery of blood clotting agent |
EP1741453A3 (en) | 2005-07-07 | 2007-01-17 | Nipro Corporation | Collagen substrate, method of manufacturing the same, and method of using the same |
EP1960009B1 (en) | 2005-12-13 | 2011-11-23 | The President and Fellows of Harvard College | Scaffolds for cell transplantation |
GB2433205A (en) * | 2005-12-16 | 2007-06-20 | Ethicon Inc | Wound dressing comprising a strong cation exchange resin |
US20070248653A1 (en) * | 2006-04-20 | 2007-10-25 | Cochrum Kent C | Hemostatic compositions and methods for controlling bleeding |
US8938898B2 (en) | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
US7968114B2 (en) * | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US7604819B2 (en) | 2006-05-26 | 2009-10-20 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8202532B2 (en) | 2006-05-26 | 2012-06-19 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US20070276308A1 (en) * | 2006-05-26 | 2007-11-29 | Huey Raymond J | Hemostatic agents and devices for the delivery thereof |
US20080014251A1 (en) * | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
US8623842B2 (en) | 2006-09-27 | 2014-01-07 | Hemostasis, Llc | Hemostatic agent and method |
CN100453122C (en) * | 2006-09-29 | 2009-01-21 | 沈晶 | Hemostatic micro-granules and its prepn. method |
US8414550B2 (en) * | 2006-09-29 | 2013-04-09 | Lexion Medical, Llc | System and method to vent gas from a body cavity |
US8551139B2 (en) | 2006-11-30 | 2013-10-08 | Cook Medical Technologies Llc | Visceral anchors for purse-string closure of perforations |
EP2150183B1 (en) | 2007-05-31 | 2013-03-20 | Cook Medical Technologies LLC | Suture lock |
WO2009002401A2 (en) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
US20090162406A1 (en) * | 2007-09-05 | 2009-06-25 | Z-Medica Corporation | Wound healing with zeolite-based hemostatic devices |
CA2709337A1 (en) * | 2007-12-20 | 2009-07-02 | The University Of Queensland | Haemostasis- modulating compositions and uses therefor |
CN104888264B (en) | 2008-01-14 | 2018-01-09 | 北京环球利康科技有限公司 | Biocompatible hemostatic, prevent adhesion, the modified starch material of promoting healing, surgery closing |
WO2009102787A2 (en) * | 2008-02-12 | 2009-08-20 | Boston Scientific Scimed, Inc. | Medical implants with polysaccharide drug eluting coatings |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
US8585646B2 (en) | 2008-03-03 | 2013-11-19 | Lexion Medical, Llc | System and method to vent gas from a body cavity |
US9061087B2 (en) * | 2008-03-04 | 2015-06-23 | Hemostasis, Llc | Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor |
US8828358B2 (en) * | 2008-03-11 | 2014-09-09 | Materials Modifications, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide |
US8852558B2 (en) * | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
US9707251B2 (en) | 2008-03-11 | 2017-07-18 | Materials Modification, Inc. | Siloxane-based artificial blockage to control bleeding |
MX338212B (en) | 2008-04-11 | 2016-04-07 | Univ Virginia Commonwealth | Electrospun dextran fibers and devices formed therefrom. |
US10046081B2 (en) | 2008-04-11 | 2018-08-14 | The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. | Electrospun dextran fibers and devices formed therefrom |
AU2009244462B2 (en) | 2008-05-06 | 2013-04-11 | Cook Medical Technologies Llc | Apparatus and methods for delivering therapeutic agents |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
WO2010053737A1 (en) * | 2008-10-29 | 2010-05-14 | Wilson-Cook Medical, Inc. | Endoscopic sheet delivery |
AU2009324646B2 (en) * | 2008-12-11 | 2013-02-14 | Cook Medical Technologies Llc | Endoscopic sheet rolling system |
WO2010074949A1 (en) | 2008-12-23 | 2010-07-01 | Wilson-Cook Medical Inc. | Apparatus and methods for containing and delivering therapeutic agents |
US8647368B2 (en) | 2009-04-03 | 2014-02-11 | Cook Medical Technologies Llc | Tissue anchors and medical devices for rapid deployment of tissue anchors |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
WO2010136588A2 (en) | 2009-05-28 | 2010-12-02 | Profibrix B.V. | Dry powder fibrin sealant |
US9101744B2 (en) | 2009-05-29 | 2015-08-11 | Cook Medical Technologies Llc | Systems and methods for delivering therapeutic agents |
US8118777B2 (en) | 2009-05-29 | 2012-02-21 | Cook Medical Technologies Llc | Systems and methods for delivering therapeutic agents |
AU2010278702C1 (en) | 2009-07-31 | 2016-07-14 | Forsyth Dental Infirmary For Children | Programming of cells for tolerogenic therapies |
US20110052663A1 (en) * | 2009-09-01 | 2011-03-03 | Hemostasis, Llc | Hemostatic Sponge with Enzyme and Method of Manufacture |
EP2542230A4 (en) | 2010-03-05 | 2013-08-28 | Harvard College | Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
US20110237994A1 (en) * | 2010-03-25 | 2011-09-29 | Combat Medical Systems, Llc | Void-filling wound dressing |
EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
US8858969B2 (en) | 2010-09-22 | 2014-10-14 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
KR102155383B1 (en) | 2010-10-06 | 2020-09-11 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Injectable, pore-forming hydrogels for materials-based cell therapies |
WO2012057751A1 (en) * | 2010-10-27 | 2012-05-03 | Empire Technology Development Llc | Crosslinked cellulosic polymers |
US9603894B2 (en) | 2010-11-08 | 2017-03-28 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
WO2012149358A1 (en) | 2011-04-28 | 2012-11-01 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
AU2012261848B2 (en) | 2011-06-03 | 2017-06-15 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
WO2013052577A1 (en) * | 2011-10-04 | 2013-04-11 | Z-Medica, Llc | Hemostatic fibrous material |
US20130096479A1 (en) | 2011-10-18 | 2013-04-18 | St. Teresa Medical, Inc. | Method of forming hemostatic products |
CN102551896B (en) * | 2012-01-19 | 2013-08-07 | 河南科技大学 | Disposable counting brain cotton aseptic package tray |
PT2838515T (en) | 2012-04-16 | 2020-02-25 | Harvard College | Mesoporous silica compositions for modulating immune responses |
KR101945031B1 (en) | 2012-06-22 | 2019-02-01 | 지-메디카 엘엘씨 | Hemostatic devices |
US9867931B2 (en) | 2013-10-02 | 2018-01-16 | Cook Medical Technologies Llc | Therapeutic agents for delivery using a catheter and pressure source |
US11931227B2 (en) | 2013-03-15 | 2024-03-19 | Cook Medical Technologies Llc | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding |
US10016524B2 (en) | 2013-04-11 | 2018-07-10 | President And Fellows Of Harvard College | Prefabricated alginate-drug bandages |
GB2514592A (en) * | 2013-05-30 | 2014-12-03 | Medtrade Products Ltd | Degradable haemostat composition |
US9555157B2 (en) | 2013-11-12 | 2017-01-31 | St. Teresa Medical, Inc. | Method of inducing hemostasis in a wound |
JP7348708B2 (en) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Combination vaccine device and method for killing cancer cells |
ES2864658T3 (en) | 2014-05-05 | 2021-10-14 | Advanced Medical Solutions Israel Sealantis Ltd | Biological adhesives and sealants and methods of using them |
US10137219B2 (en) | 2014-08-04 | 2018-11-27 | James F. Drake | Coherent blood coagulation structure of water-insoluble chitosan and water-dispersible starch coating |
EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
EP3344299B1 (en) * | 2015-09-01 | 2021-08-11 | Baxter International Inc | Hemostatic material |
WO2017083050A1 (en) | 2015-11-12 | 2017-05-18 | St. Teresa Medical, Inc. | A method of sealing a durotomy |
US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
JP2019522486A (en) | 2016-07-13 | 2019-08-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Antigen presenting cell mimetic scaffold and methods for making and using the same |
CA3033757A1 (en) * | 2016-10-11 | 2018-04-19 | St. Teresa Medical, Inc. | Hemostatic products |
US20180110735A1 (en) * | 2016-10-20 | 2018-04-26 | Bard Access Systems, Inc. | Antimicrobial alginate-based microparticles and related materials and methods |
US10953130B2 (en) | 2017-08-31 | 2021-03-23 | Victor Matthew Phillips | Solid hemostatic composition and methods of making the same |
US10953128B2 (en) | 2017-11-02 | 2021-03-23 | St. Teresa Medical, Inc. | Fibrin sealant products |
EP3717028A1 (en) * | 2017-11-28 | 2020-10-07 | Baxter International Inc | Wound-treating absorbent |
CN108144128B (en) * | 2018-02-07 | 2021-11-05 | 陕西佰傲再生医学有限公司 | Multi-time cross-linking breast patch and preparation method thereof |
CN109125790A (en) * | 2018-08-25 | 2019-01-04 | 山东康力医疗器械科技有限公司 | A kind of styptic sponge structure made of chitosan |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US27327A (en) * | 1860-02-28 | Improvement in apparatus for distilling coal-oil | ||
US854715A (en) * | 1905-10-26 | 1907-05-28 | Gen Electric | Combined coupling and bearing. |
US959080A (en) * | 1908-08-05 | 1910-05-24 | Samuel B Sheldon | Process for coking coal. |
US974054A (en) * | 1910-01-20 | 1910-10-25 | Frank Guy | Acetylene-lamp. |
US1454055A (en) * | 1920-04-17 | 1923-05-08 | Klamroth Wilfried | Razor-blade holder |
US2387642A (en) | 1942-03-25 | 1945-10-23 | Calhoun Vernon | Hemostat and method of forming same |
US3206361A (en) | 1962-06-19 | 1965-09-14 | Johnson & Johnson | Stabilized methylaminoacetocatechol hemostatic wound dressing |
US3507851A (en) | 1966-03-24 | 1970-04-21 | Victor Ghetie | Synthesis derivatives of agarose having application in electrophoresis on gel and in chromatography |
US3671280A (en) * | 1970-12-04 | 1972-06-20 | David F Smith | Plaster of paris bandages to make casts of improved strength,water-resistance and physiological properties |
DE2247163A1 (en) | 1972-09-26 | 1974-03-28 | Merck Patent Gmbh | CARRIER MATRIX FOR FIXING BIOLOGICALLY ACTIVE SUBSTANCES AND THE PROCESS FOR THEIR PRODUCTION |
US3810473A (en) | 1972-12-04 | 1974-05-14 | Avicon Inc | Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties |
FR2234311B1 (en) | 1973-06-21 | 1976-04-30 | Air Liquide | |
DE2644678A1 (en) | 1976-10-02 | 1978-04-06 | Dynamit Nobel Ag | METHOD OF MANUFACTURING FUNCTIONAL CELLULOSES |
US4175183A (en) | 1977-03-01 | 1979-11-20 | Development Finance Corporation Of New Zealand | Hydroxyalkylated cross-linked regenerated cellulose and method of preparation thereof |
GB1594389A (en) | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
AT359653B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
AT359652B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
DE3036033A1 (en) | 1980-09-24 | 1982-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | POWDERED WOUND TREATMENT AND METHOD FOR THE PRODUCTION THEREOF |
US4793336A (en) | 1981-03-25 | 1988-12-27 | Wang Paul Y | Wound coverings and processes for their preparation |
EP0068047B1 (en) | 1981-06-25 | 1986-07-23 | Serapharm GmbH & Co. KG | Enriched plasma derivative for promoting wound sealing and wound healing |
US4405324A (en) | 1981-08-24 | 1983-09-20 | Morca, Inc. | Absorbent cellulosic structures |
DE3270438D1 (en) | 1981-09-30 | 1986-05-15 | Leipzig Arzneimittel | Absorbent wound dressing and processes for its production |
SE430218B (en) | 1981-12-30 | 1983-10-31 | Blombaeck E G B | FILTER AND SET TO MAKE A SADANT |
US4543410A (en) * | 1982-06-21 | 1985-09-24 | Morca, Inc. | Absorbent cellulosic base structures |
US5059654A (en) | 1983-02-14 | 1991-10-22 | Cuno Inc. | Affinity matrices of modified polysaccharide supports |
SE437270B (en) | 1983-07-19 | 1985-02-18 | Pharmacia Ab | SEPARATION MATERIAL OF THE CIRCUIT AGAROS AND ITS PREPARATION SEPARATION MATERIAL OF THE CIVIL-AGAROS AND ITS PREPARATION |
US4549653A (en) | 1983-09-06 | 1985-10-29 | Johnson & Johnson Products, Inc. | Adhesive bandage and package |
SE460017B (en) | 1984-03-14 | 1989-09-04 | Landstingens Inkopscentral | BACTERY-ADDRESSING COMPOSITION IN WATER-SOLUBLE FORM |
US4738849A (en) | 1984-06-28 | 1988-04-19 | Interface Biomedical Laboratories Corp. | Composite medical articles for application to wounds and method for producing same |
US4626253A (en) | 1984-10-05 | 1986-12-02 | Johnson & Johnson Products, Inc. | Surgical hemostat comprising oxidized cellulose |
JPS61122222A (en) | 1984-11-19 | 1986-06-10 | Koken:Kk | Hemostatic agent composed of collagen or gelatin and protamine |
NO166836C (en) | 1985-03-14 | 1991-09-11 | Univ California | PROCEDURE FOR TREATMENT OF AN ORGAN TRANSPLANT. |
SE458525B (en) | 1985-05-23 | 1989-04-10 | Pharmacia Ab | PROCEDURE FOR CROSS-BINDING OF A PORO'S AGAR OR AGARO GEL |
US4616644A (en) | 1985-06-14 | 1986-10-14 | Johnson & Johnson Products, Inc. | Hemostatic adhesive bandage |
US4946953A (en) | 1986-10-16 | 1990-08-07 | Kanebo, Ltd. | Fine cellulose particles and process for production thereof employing coagulated viscose |
US5225047A (en) | 1987-01-20 | 1993-07-06 | Weyerhaeuser Company | Crosslinked cellulose products and method for their preparation |
US4777249A (en) | 1987-03-13 | 1988-10-11 | Teepak, Inc. | Crosslinked cellulose aminomethanate |
GB8705985D0 (en) | 1987-03-13 | 1987-04-15 | Geistlich Soehne Ag | Dressings |
GB8709498D0 (en) | 1987-04-22 | 1987-05-28 | Bay M | Wound dressing |
US4848329A (en) * | 1987-09-01 | 1989-07-18 | Herbert Dardik | Mucoid absorbing dressing |
JPH06104116B2 (en) | 1988-11-29 | 1994-12-21 | 三菱化成株式会社 | Wound dressing |
US5077210A (en) | 1989-01-13 | 1991-12-31 | Eigler Frances S | Immobilization of active agents on substrates with a silane and heterobifunctional crosslinking agent |
US5015476A (en) | 1989-08-11 | 1991-05-14 | Paravax, Inc. | Immunization implant and method |
US5185001A (en) | 1990-01-18 | 1993-02-09 | The Research Foundation Of State University Of New York | Method of preparing autologous plasma fibrin and application apparatus therefor |
US5081041A (en) * | 1990-04-03 | 1992-01-14 | Minnesota Mining And Manufacturing Company | Ionic component sensor and method for making and using same |
US5098417A (en) | 1990-04-12 | 1992-03-24 | Ricoh Kyosan, Inc. | Cellulosic wound dressing with an active agent ionically absorbed thereon |
US5241009A (en) | 1990-05-07 | 1993-08-31 | Kimberly-Clark Corporation | Polymeric composition containing carboxy nueutralized with lithium or potassium |
NO171069C (en) | 1990-05-29 | 1993-01-20 | Protan Biopolymer As | COVALENT CIRCUIT, STRONGLY SWELLING ALKALIMETAL AND AMMONIUM ALGINATE GELS, AND PROCEDURES FOR PREPARING THEREOF |
US5196190A (en) | 1990-10-03 | 1993-03-23 | Zenith Technology Corporation, Limited | Synthetic skin substitutes |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5279955A (en) | 1991-03-01 | 1994-01-18 | Pegg Randall K | Heterofunctional crosslinking agent for immobilizing reagents on plastic substrates |
FR2679573B1 (en) | 1991-07-25 | 1993-09-24 | Perfojet Sa | PROCESS FOR THE MANUFACTURE OF A WASHABLE, COTTON-BASED TABLECLOTH, AND TABLECLOTH THUS OBTAINED. |
US5804213A (en) | 1991-10-09 | 1998-09-08 | Lectec Corporation | Biologically active aqueous gel wound dressing |
US5584827A (en) | 1992-05-18 | 1996-12-17 | Ultracell Medical Technologies, Inc | Nasal-packing article |
US5521079A (en) | 1994-01-24 | 1996-05-28 | The Regents Of The University Of California | Microcapsule generating system containing an air knife and method of encapsulating |
US5578314A (en) | 1992-05-29 | 1996-11-26 | The Regents Of The University Of California | Multiple layer alginate coatings of biological tissue for transplantation |
WO1994013266A1 (en) | 1992-05-29 | 1994-06-23 | The Regents Of The University Of California | Novel electrostatic process for manufacturing coated transplants and products |
US6001387A (en) | 1992-05-29 | 1999-12-14 | The Reguents Of The University Of California | Spin disk encapsulation apparatus and method of use |
US5643594A (en) | 1992-05-29 | 1997-07-01 | The Regents Of The University Of California | Spin encapsulation apparatus and method of use |
US5429821A (en) | 1992-05-29 | 1995-07-04 | The Regents Of The University Of California | Non-fibrogenic high mannuronate alginate coated transplants, processes for their manufacture, and methods for their use |
AU4402793A (en) | 1992-05-29 | 1993-12-30 | Regents Of The University Of California, The | Coated transplant and method for making same |
US5470576A (en) * | 1992-06-08 | 1995-11-28 | The Kendall Company | Process for preparing the alginate-containing wound dressing |
CN1091315A (en) | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | Fibrin sealant compositions and using method thereof |
US5679372A (en) | 1992-11-02 | 1997-10-21 | Yasuhiko Shimizu | Absorbable topical hemostat |
GB9225581D0 (en) | 1992-12-08 | 1993-01-27 | Courtaulds Plc | Wound dressings |
US5330974A (en) | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
GB2275686B (en) * | 1993-03-03 | 1997-04-30 | Johnson & Johnson Medical | Swellable wound dressing materials |
DE69427716T2 (en) | 1993-03-10 | 2002-06-13 | Nichiban Kk | Adhesive bandage for hemostasis |
US5681579A (en) | 1993-03-22 | 1997-10-28 | E.R. Squibb & Sons, Inc. | Polymeric support wound dressing |
US5328687A (en) | 1993-03-31 | 1994-07-12 | Tri-Point Medical L.P. | Biocompatible monomer and polymer compositions |
US5624669A (en) | 1993-03-31 | 1997-04-29 | Tri-Point Medical Corporation | Method of hemostatic sealing of blood vessels and internal organs |
EP0726749B1 (en) | 1993-11-03 | 2004-08-11 | Clarion Pharmaceuticals, Inc. | Hemostatic patch |
US5876742A (en) * | 1994-01-24 | 1999-03-02 | The Regents Of The University Of California | Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method of preparation thereof |
US5502092A (en) | 1994-02-18 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Biocompatible porous matrix of bioabsorbable material |
US5406671A (en) | 1994-02-25 | 1995-04-18 | Green; Daniel K. | Trowel |
US5514377A (en) | 1994-03-08 | 1996-05-07 | The Regents Of The University Of California | In situ dissolution of alginate coatings of biological tissue transplants |
DE69530553T2 (en) | 1994-05-13 | 2004-03-25 | KURARAY CO., LTD, Kurashiki | MEDICAL POLYMER GEL |
US5502042A (en) | 1994-07-22 | 1996-03-26 | United States Surgical Corporation | Methods and compositions for treating wounds |
WO1996009115A1 (en) * | 1994-09-21 | 1996-03-28 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for interleukins, method of removal thereof by adsorption, and device for adsorption |
US5585007A (en) | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5614204A (en) | 1995-01-23 | 1997-03-25 | The Regents Of The University Of California | Angiographic vascular occlusion agents and a method for hemostatic occlusion |
US5733545A (en) | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US5900245A (en) * | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
US5795581A (en) | 1995-03-31 | 1998-08-18 | Sandia Corporation | Controlled release of molecular components of dendrimer/bioactive complexes |
US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
US5795570A (en) | 1995-04-07 | 1998-08-18 | Emory University | Method of containing core material in microcapsules |
EP0821573A4 (en) | 1995-04-19 | 2000-08-09 | St Jude Medical | Matrix substrate for a viable body tissue-derived prosthesis and method for making the same |
DE19521324C1 (en) | 1995-06-12 | 1996-10-31 | Immuno Ag | Tissue adhesive and use thereof as a hemostatic |
US6121508A (en) * | 1995-12-29 | 2000-09-19 | 3M Innovative Properties Company | Polar, lipophilic pressure-sensitive adhesive compositions and medical devices using same |
US5800372A (en) | 1996-01-09 | 1998-09-01 | Aerojet-General Corporation | Field dressing for control of exsanguination |
US5696101A (en) | 1996-04-16 | 1997-12-09 | Eastman Chemical Company | Oxidized cellulose and vitamin E blend for topical hemostatic applications |
DE69719754D1 (en) | 1996-05-23 | 2003-04-17 | Xoma Technology Ltd | THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA |
US5811151A (en) | 1996-05-31 | 1998-09-22 | Medtronic, Inc. | Method of modifying the surface of a medical device |
US6706690B2 (en) * | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
US5834008A (en) | 1996-09-19 | 1998-11-10 | U.S. Biomaterials Corp. | Composition and method for acceleration of wound and burn healing |
US5844087A (en) | 1996-11-05 | 1998-12-01 | Bayer Corporation | Method and device for delivering fibrin glue |
US5817381A (en) | 1996-11-13 | 1998-10-06 | Agricultural Utilization Research Institute | Cellulose fiber based compositions and film and the process for their manufacture |
US6083522A (en) * | 1997-01-09 | 2000-07-04 | Neucoll, Inc. | Devices for tissue repair and methods for preparation and use thereof |
US5846213A (en) | 1997-06-16 | 1998-12-08 | The University Of Western Ontario | Cellulose membrane and method for manufacture thereof |
WO1999001143A1 (en) * | 1997-07-03 | 1999-01-14 | Orquest, Inc. | Cross-linked polysaccharide drug carrier |
ZA987019B (en) * | 1997-08-06 | 1999-06-04 | Focal Inc | Hemostatic tissue sealants |
DE19813663A1 (en) * | 1998-03-27 | 1999-10-07 | Beiersdorf Ag | Wound dressings for removing disruptive factors from wound fluid |
US6200595B1 (en) * | 1998-04-24 | 2001-03-13 | Kuraray Co., Ltd. | Medical adhesive |
US6200328B1 (en) * | 1998-05-01 | 2001-03-13 | Sub Q, Incorporated | Device and method for facilitating hemostasis of a biopsy tract |
US6056970A (en) * | 1998-05-07 | 2000-05-02 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
US6261679B1 (en) * | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
US6454787B1 (en) * | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
KR20010010151A (en) * | 1999-07-16 | 2001-02-05 | 김윤 | Antiadhesion barrier containing water-soluble alginate and carboxymethyl cellulose as major components and preparation method thereof |
EP1210130A1 (en) * | 1999-08-20 | 2002-06-05 | Beaulieu, André | Solid wound healing formulations containing fibronectin |
US6391048B1 (en) * | 2000-01-05 | 2002-05-21 | Integrated Vascular Systems, Inc. | Integrated vascular device with puncture site closure component and sealant and methods of use |
KR100721752B1 (en) * | 2000-01-24 | 2007-05-25 | 쿠라레 메디카루 가부시키가이샤 | Water-swellable polymer gel and process for preparing the same |
US6627785B1 (en) * | 2000-02-29 | 2003-09-30 | Virginia Commwealth University | Wound dressings with protease-lowering activity |
-
2002
- 2002-12-31 AU AU2002361902A patent/AU2002361902A1/en not_active Abandoned
- 2002-12-31 MX MXPA04006438A patent/MXPA04006438A/en active IP Right Grant
- 2002-12-31 JP JP2003557435A patent/JP2005514105A/en active Pending
- 2002-12-31 CA CA002471994A patent/CA2471994A1/en not_active Abandoned
- 2002-12-31 US US10/334,864 patent/US7101862B2/en not_active Expired - Fee Related
- 2002-12-31 WO PCT/US2002/041748 patent/WO2003057072A2/en active Application Filing
- 2002-12-31 EP EP02797532A patent/EP1469865A4/en not_active Withdrawn
-
2006
- 2006-02-17 US US11/357,770 patent/US20060141018A1/en not_active Abandoned
-
2007
- 2007-08-06 US US11/890,321 patent/US20080020026A1/en not_active Abandoned
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140370074A1 (en) * | 2007-11-05 | 2014-12-18 | Technion Research & Development Foundation Ltd. | Adhering composition and methods of applying the same |
US20090275904A1 (en) * | 2008-05-02 | 2009-11-05 | Sardesai Neil Rajendra | Sheet assemblies with releasable medicaments |
US9216234B2 (en) | 2009-06-01 | 2015-12-22 | Technion Research & Development Foundation Ltd. | Sealants, manufacturing thereof, and application thereof |
CN102497890A (en) * | 2009-06-01 | 2012-06-13 | 特克尼雍技术研究与发展基金会有限公司 | Sealants, manufacturing thereof, and applications thereof |
WO2010140146A3 (en) * | 2009-06-01 | 2011-06-30 | Technion - Research & Development Foundation Ltd | Sealants, manufacturing thereof, and applications thereof |
WO2010140146A2 (en) | 2009-06-01 | 2010-12-09 | Technion - Research & Development Foundation Ltd | Sealants, manufacturing thereof, and applications thereof |
US20160068714A1 (en) * | 2009-06-01 | 2016-03-10 | Technion Research & Development Foundation Ltd. | Sealants, manufacturing thereof and applications thereof |
WO2014145714A1 (en) * | 2013-01-17 | 2014-09-18 | Tattoo Innovations, Inc. | Hydrogel tattoo protection and aftercare system |
US20190054203A1 (en) * | 2015-11-08 | 2019-02-21 | Omrix Biopharmaceuticals Ltd. | Hemostatic mixture of cellulose-based short and long fibers |
US20190060514A1 (en) * | 2015-11-08 | 2019-02-28 | Omrix Biopharmaceuticals Ltd. | Hemostatic Composition |
US10960105B2 (en) | 2015-11-08 | 2021-03-30 | Omrix Biopharmaceuticals Ltd. | Hemostatic composition |
US11007300B2 (en) * | 2015-11-08 | 2021-05-18 | Omrix Biopharmaceuticals Ltd. | Hemostatic composition |
US11007301B2 (en) * | 2015-11-08 | 2021-05-18 | Omrix Biopharmaceuticals Ltd. | Hemostatic mixture of cellulose-based short and long fibers |
US11712495B2 (en) | 2015-11-08 | 2023-08-01 | Omrix Biopharmaceuticals Ltd. | Hemostatic mixture of cellulose-based short and long fibers |
Also Published As
Publication number | Publication date |
---|---|
AU2002361902A8 (en) | 2003-07-24 |
WO2003057072A3 (en) | 2003-10-30 |
MXPA04006438A (en) | 2005-06-08 |
CA2471994A1 (en) | 2003-07-17 |
AU2002361902A1 (en) | 2003-07-24 |
US20030175327A1 (en) | 2003-09-18 |
WO2003057072A8 (en) | 2004-07-08 |
EP1469865A2 (en) | 2004-10-27 |
JP2005514105A (en) | 2005-05-19 |
EP1469865A4 (en) | 2010-04-14 |
US7101862B2 (en) | 2006-09-05 |
US20060141018A1 (en) | 2006-06-29 |
WO2003057072A2 (en) | 2003-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7101862B2 (en) | Hemostatic compositions and methods for controlling bleeding | |
Qiao et al. | A mussel-inspired supramolecular hydrogel with robust tissue anchor for rapid hemostasis of arterial and visceral bleedings | |
EP1718147B1 (en) | Hemostatic agent for topical and internal use | |
US20070248653A1 (en) | Hemostatic compositions and methods for controlling bleeding | |
US6056970A (en) | Compositions comprising hemostatic compounds and bioabsorbable polymers | |
US20180036338A1 (en) | Flowable hemostatic composition | |
TWI353829B (en) | Dry flexible hemostatic material and method for pr | |
JP2004290650A (en) | Hemostatic bandage for injury and method of making thereof | |
CN102600013A (en) | Medical flocking hemostasis material, preparation thereof and application | |
KR101735899B1 (en) | Biodegradable non-woven material for medical purposes | |
US20100260845A1 (en) | Biocompatible and Biodegradable Biopolymer Matrix | |
WO2009043839A1 (en) | Coalescing carboxymethylchitosan-based materials | |
RU2249467C2 (en) | Medicinal material and products based upon this material | |
US10137219B2 (en) | Coherent blood coagulation structure of water-insoluble chitosan and water-dispersible starch coating | |
CN114306715A (en) | Dry pad comprising thrombin and pectin | |
KR102615766B1 (en) | Adhesive composition for in-body absorbable reinforcement materials comprising chitosan and gelatin and manufacturing method thereof | |
JPS624232A (en) | Hemostatic agent | |
CA2959946C (en) | A coherent blood coagulation structure of water-insoluble chitosan and water-dispersible starch coating | |
CN109568635B (en) | In-situ expansion high-water-absorption hemostatic material and preparation method thereof | |
CN114832148A (en) | Hemostatic material with antibacterial and anti-inflammatory functions and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARES LABORATORIES, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COCHRUM, KENT C.;JEMTRUD, SUSAN;REEL/FRAME:022083/0757;SIGNING DATES FROM 20030908 TO 20031105 |
|
AS | Assignment |
Owner name: CROSSLINK-D, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARES LABORATORIES, LLC;REEL/FRAME:022113/0479 Effective date: 20050518 |
|
AS | Assignment |
Owner name: INTERNATIONAL MANUFACTURING GROUP, INC., CALIFORNI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CROSSLINK-D, INC.;REEL/FRAME:022831/0529 Effective date: 20090217 Owner name: THEIS, JEROLD, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CROSSLINK-D, INC.;REEL/FRAME:022831/0529 Effective date: 20090217 |
|
AS | Assignment |
Owner name: FISH & RICHARDSON P.C., MASSACHUSETTS Free format text: LIEN;ASSIGNOR:CROSSLINK-D, INC.;REEL/FRAME:023627/0209 Effective date: 20091209 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: LIGHTY, CRAIG E., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THEIS, JEROLD, DR.;REEL/FRAME:028434/0986 Effective date: 20101028 |